WO2019089034A1 - Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation - Google Patents
Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation Download PDFInfo
- Publication number
- WO2019089034A1 WO2019089034A1 PCT/US2017/059758 US2017059758W WO2019089034A1 WO 2019089034 A1 WO2019089034 A1 WO 2019089034A1 US 2017059758 W US2017059758 W US 2017059758W WO 2019089034 A1 WO2019089034 A1 WO 2019089034A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- cells
- transfected
- cell deformation
- flow
- Prior art date
Links
- 238000012384 transportation and delivery Methods 0.000 title abstract description 131
- 239000012528 membrane Substances 0.000 title abstract description 22
- 108091033409 CRISPR Proteins 0.000 claims abstract description 101
- 238000000034 method Methods 0.000 claims abstract description 76
- 239000000463 material Substances 0.000 claims abstract description 71
- 239000013612 plasmid Substances 0.000 claims description 67
- 108020004459 Small interfering RNA Proteins 0.000 claims description 25
- 239000012530 fluid Substances 0.000 claims description 23
- 230000012292 cell migration Effects 0.000 claims description 22
- 230000005012 migration Effects 0.000 claims description 22
- 238000013508 migration Methods 0.000 claims description 22
- 229910052710 silicon Inorganic materials 0.000 claims description 17
- 239000010703 silicon Substances 0.000 claims description 17
- 239000000758 substrate Substances 0.000 claims description 15
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 12
- 239000002002 slurry Substances 0.000 claims description 12
- 230000003399 chemotactic effect Effects 0.000 claims description 6
- 230000007246 mechanism Effects 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 230000000717 retained effect Effects 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 3
- 108091028113 Trans-activating crRNA Proteins 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 abstract description 599
- 238000010362 genome editing Methods 0.000 abstract description 48
- 108090000623 proteins and genes Proteins 0.000 abstract description 31
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 abstract description 23
- 230000001404 mediated effect Effects 0.000 abstract description 23
- 230000035772 mutation Effects 0.000 abstract description 20
- 238000004458 analytical method Methods 0.000 abstract description 18
- 230000008901 benefit Effects 0.000 abstract description 15
- 230000003833 cell viability Effects 0.000 abstract description 14
- 206010025323 Lymphomas Diseases 0.000 abstract description 13
- 101710163270 Nuclease Proteins 0.000 abstract description 12
- 230000001052 transient effect Effects 0.000 abstract description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 210000001671 embryonic stem cell Anatomy 0.000 abstract description 7
- 229920002521 macromolecule Polymers 0.000 abstract description 7
- 238000011160 research Methods 0.000 abstract description 7
- 238000013459 approach Methods 0.000 abstract description 4
- 238000004520 electroporation Methods 0.000 abstract description 4
- 238000012937 correction Methods 0.000 abstract description 3
- 238000010363 gene targeting Methods 0.000 abstract description 3
- 230000003834 intracellular effect Effects 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 239000012620 biological material Substances 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 31
- 108010081734 Ribonucleoproteins Proteins 0.000 description 31
- 238000002474 experimental method Methods 0.000 description 29
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 28
- 238000005516 engineering process Methods 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 23
- 239000004205 dimethyl polysiloxane Substances 0.000 description 23
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 23
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 20
- 210000004379 membrane Anatomy 0.000 description 19
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 239000012091 fetal bovine serum Substances 0.000 description 17
- 230000008685 targeting Effects 0.000 description 16
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 15
- 210000000170 cell membrane Anatomy 0.000 description 15
- 238000013461 design Methods 0.000 description 15
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 229960005322 streptomycin Drugs 0.000 description 11
- 229920002307 Dextran Polymers 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 238000004088 simulation Methods 0.000 description 10
- 230000035882 stress Effects 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 9
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 210000004986 primary T-cell Anatomy 0.000 description 9
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 8
- 229940127093 camptothecin Drugs 0.000 description 8
- 239000010432 diamond Substances 0.000 description 8
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 7
- 108020004682 Single-Stranded DNA Proteins 0.000 description 7
- 230000001464 adherent effect Effects 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 229910003460 diamond Inorganic materials 0.000 description 7
- -1 polydimethylsiloxane Polymers 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 6
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000012300 Sequence Analysis Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 210000000172 cytosol Anatomy 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000005090 green fluorescent protein Substances 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108091093088 Amplicon Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000002716 delivery method Methods 0.000 description 5
- 238000003197 gene knockdown Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000009437 off-target effect Effects 0.000 description 5
- 229920002120 photoresistant polymer Polymers 0.000 description 5
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 4
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 4
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 229910000831 Steel Inorganic materials 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000005782 double-strand break Effects 0.000 description 4
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000036438 mutation frequency Effects 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 229950010131 puromycin Drugs 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000010959 steel Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 3
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 3
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 3
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 3
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 3
- 239000012124 Opti-MEM Substances 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000035605 chemotaxis Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010230 functional analysis Methods 0.000 description 3
- 238000003209 gene knockout Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 230000006780 non-homologous end joining Effects 0.000 description 3
- 238000000206 photolithography Methods 0.000 description 3
- 208000012584 pre-descemet corneal dystrophy Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- 108091027305 Heteroduplex Proteins 0.000 description 2
- 101000970025 Homo sapiens NUAK family SNF1-like kinase 2 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 102100021733 NUAK family SNF1-like kinase 2 Human genes 0.000 description 2
- 101150054125 Nuak2 gene Proteins 0.000 description 2
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 2
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000000504 Tumor Suppressor p53-Binding Protein 1 Human genes 0.000 description 2
- 108010041385 Tumor Suppressor p53-Binding Protein 1 Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012776 electronic material Substances 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000009616 inductively coupled plasma Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000009832 plasma treatment Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000002174 soft lithography Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003239 susceptibility assay Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000005051 trimethylchlorosilane Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- FBDOJYYTMIHHDH-OZBJMMHXSA-N (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-2,4,6,8,10,14,20-heptaen-18-one Chemical compound CC[C@@]1(O)C(=O)OCC2=CN3Cc4cc5ccccc5nc4C3C=C12 FBDOJYYTMIHHDH-OZBJMMHXSA-N 0.000 description 1
- 101150090986 1.5 gene Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 102100035767 Adrenocortical dysplasia protein homolog Human genes 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 231100001074 DNA strand break Toxicity 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 244000223021 Elaeagnus orientalis Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940123611 Genome editing Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 101000942966 Mus musculus Leukemia inhibitory factor Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 1
- 101710132081 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229940127174 UCHT1 Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008970 bacterial immunity Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000012361 double-strand break repair Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000001159 endocytotic effect Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000004966 intestinal stem cell Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 230000009438 off-target cleavage Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000002220 organoid Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/02—Membranes; Filters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B3/00—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form
- B32B3/26—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form characterised by a particular shape of the outline of the cross-section of a continuous layer; characterised by a layer with cavities or internal voids ; characterised by an apertured layer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/16—Microfluidic devices; Capillary tubes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Definitions
- This invention relates to cell transfection in general, and more particularly to CRISPR-Cas9 delivery to hard-to-transfect cells.
- the CRISPR (clustered regularly interspaced short palindromic repeats) -Cas (CRISPR-associated) nuclease system is an easy-to-use, highly specific, efficient, and multiplexable genome editing tool that has been used in various organisms, including human and mouse cell lines. See P. Mali, L. Yang, K. M. Esvelt, J. Aach, M. Guell, J. E. DiCarlo, J. E. Norville, G. M. Church, RNA guided human genome engineering via Cas9.
- sgRNA single-guide RNA
- Cas9 can be easily programmed to induce DNA double-strand breaks through RNA guides, which can generate insertions and
- intracellular delivery techniques use liposomes or polymeric nanoparticles to induce cell membrane poration or endocytosis. See F. Heitz, M. C. Morris, G. Divita, Twenty years of cell-penetrating peptides : From molecular mechanisms to therapeutics . Br. J.
- Electroporation is an attractive alternative for many applications and allows highly efficient RNA-guided genome editing via delivery of purified Cas9
- retrovirus, or lentivirus -mediated delivery of sgRNA and Cas9 is often associated with uncontrolled
- Rapid mechanical deformation of cells can produce transient membrane disruptions that facilitate passive diffusion of material into the cytosol.
- Membrane deformation-based microfluidic devices have been used in the delivery of a range of materials such as carbon nanotubes, proteins, and short interfering RNAs (siRNAs) . They have been used for delivering transcription factors for cell reprogramming . See A. Sharei, J. Zoldan, A. Adamo, W. Y. Sim, N. Cho, E. Jackson, S. Mao, S.
- Microfluidic membrane deformation has the
- the present invention comprises the provision and use of a novel microfluidic platform which optimizes the physical constriction in a microfluidic setup, considering both delivery efficiency and cell
- the present invention allows successful delivery of single-stranded DNA (ssDNA), siRNAs, and large-sized plasmids into different cell types, including adherent and non-adherent cells, hard-to- transfect lymphoma, and embryonic stem cells. Sequence analysis, together with biochemical and functional analyses, demonstrates highly efficient genome editing and successful generation of gene-knockout cell lines, using the present invention with different cell types.
- the new microfluidic delivery method of the present invention will facilitate RNA-guided genome editing and gene loss-of-function analysis across different cell types, especially difficult-to- transfect cells. Achievement of high genome editing efficiency in non-adherent lymphoma cells suggests that the approach utilized with the present invention also has potential for clinical use.
- a system for transfecting cells comprising:
- a microfluidic device comprising:
- a housing having a flow passageway formed therein, the flow passageway comprising a port; and a cell deformation zone formed within the flow passageway, the cell deformation zone comprising a plurality of cell deformation structures spaced laterally across the flow passageway and serially along the flow passageway, wherein the laterally- spaced cell deformation structures define a plurality of gaps therebetween, wherein each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap.
- a method for transfecting cells comprising:
- a microfluidic device comprising:
- a housing having a flow passageway formed therein, the flow passageway comprising a port;
- each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap;
- a system for transfecting cells comprising:
- a microfluidic device comprising:
- a housing having a flow passageway formed therein, the flow passageway comprising a port;
- the cell deformation zone formed within the flow passageway, the cell deformation zone comprising a plurality of cell deformation structures defining a plurality of gaps therebetween, wherein each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap;
- a plurality of cells to be transfected a plurality of cells to be transfected; and material to be transfected into the plurality of cells, wherein the material to be transfected into the plurality of cells comprises plasmids encoding sgRNA and plasmids encoding Cas9 protein.
- a method for transfecting cells comprising:
- a microfluidic device comprising:
- a housing having a flow passageway formed therein, the flow passageway comprising a port; a cell deformation zone formed within the flow passageway, the cell deformation zone
- each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap;
- transfected into the plurality of cells comprises plasmids encoding sgRNA and plasmids encoding Cas9 protein;
- a system for transfecting cells comprising:
- a microfluidic device comprising:
- a housing having a flow passageway formed therein, the flow passageway comprising a port; and a cell deformation zone formed within the flow passageway, the cell deformation zone comprising a plurality of flow channels, wherein the plurality of flow channels each comprise a first wall and a second wall, wherein the first wall and the second wall are spaced apart so as to define a flow path therebetween;
- At least one cell deformation structure extending away from the first wall of a given flow channel into the flow path of that flow channel, the at least one cell deformation structure being spaced away from the second wall of that flow channel such that a gap is disposed between the at least one cell deformation structure and the second wall, wherein the gap is sized such that a cell passing through the gap is mechanically deformed as the cell passes through that gap.
- a method for transfecting cells comprising:
- a microfluidic device comprising:
- a housing having a flow passageway formed therein, the flow passageway comprising a port;
- the plurality of flow channels each comprise a first wall and a second wall, wherein the first wall and the second wall are spaced apart so as to define a flow path therebetween; at least one cell deformation structure extending away from the first wall of a given flow channel into the flow path of that flow channel, the at least one cell deformation structure being spaced away from the second wall of that flow channel such a gap is disposed between the at least one cell deformation structure and the second wall, wherein the gap is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap; and
- a system for transfecting cells comprising:
- a microfluidic device comprising:
- a housing having a flow passageway formed therein, the flow passageway comprising a port;
- each of the cell deformation structures comprises a body and a plurality of arms extending away from the body, wherein at least two cell deformation structures are arranged parallel to one another such that a plurality of gaps exist between the plurality of arms of the cell deformation structures, and further wherein each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap.
- a method for transfecting cells comprising:
- a microfluidic device comprising:
- a housing having a flow passageway formed therein, the flow passageway comprising a port;
- each of the cell deformation structures comprises a body and a plurality of arms extending away from the body, wherein at least two cell deformation structures are arranged parallel to one another such that a plurality of gaps exist between the plurality of arms of the cell deformation structures, and further wherein each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap;
- a system for transfecting cells comprising:
- a microfluidic device comprising:
- a housing having a flow chamber formed therein, the flow chamber comprising at least one inlet ;
- the cell deformation section formed within the flow chamber, the cell deformation section comprising a plurality of cell deformation structures defining a plurality of gaps therebetween, and wherein each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap;
- the cell migration section formed within the flow chamber and fluidically connected to the cell deformation section, the cell migration section comprising a plurality of traps arrayed serially along the flow chamber and a plurality of migration
- microchannels disposed perpendicular to the
- a method for transfecting and chemotactically separating cells comprising:
- a microfluidic device comprising: a housing having a flow chamber formed therein, the flow chamber comprising at least one inlet ;
- the cell deformation section formed within the flow chamber, the cell deformation section comprising a plurality of cell deformation structures defining a plurality of gaps therebetween, and wherein each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap;
- the cell migration section formed within the flow chamber and fluidically connected to the cell deformation section, the cell migration section comprising a plurality of traps arrayed serially along the flow chamber and a plurality of migration
- microchannels disposed perpendicular to the
- Fig. 1A is a schematic view showing a novel microfluidic device formed in accordance with the present invention
- Fig. IB is a schematic view showing how plasmids encoding sgRNA and Cas9 protein can be passed into a cell using the novel microfluidic device of Fig. 1A;
- Fig. 1C is a schematic view showing further aspects of the novel microfluidic device of Fig. 1A;
- Fig. ID is a schematic view showing a cell stress simulation of a cell being passed through the novel microfluidic device of Fig. 1A;
- Figs. 2A-2F are schematic views showing
- Figs. 3A-3E are schematic views showing
- Figs. 4A-4E are schematic views showing
- FIGS. 5A-5D are schematic views showing
- Fig. 6A is a schematic view showing various cell deformation structures which may be used in a novel microfluidic device formed in accordance with the present invention
- Figs. 6B and 6C are schematic views showing experimental results of cells being passed through novel microfluidic devices formed in accordance with the present invention, wherein the various cell deformation structures of Fig. 6A have been
- Fig. 6D is a schematic view showing several novel microfluidic devices formed in accordance with the present invention being multiplexed;
- Fig. 6E is a schematic view showing experimental results of an experiment in which HEK293T and SUM159 cells were passed through a novel microfluidic device formed in accordance with the present invention
- Fig. 7 is a schematic view showing stress
- Fig. 8 is a schematic view showing flow velocity simulation of cell profusion through diamond-shaped cell deformation structures of a novel microfluidic device formed in accordance with the present
- Figs. 9A-9C are schematic views showing
- plasmids encoding GFP were passed into cells using FuGENE HD and delivery via a novel microfluidic device formed in accordance with the present invention
- Figs. 9D-9F are schematic views showing
- plasmids encoding GFP with Phosphoglycerate Kinase 1 (PGK) promoter were passed into cells using FuGENE HD and delivery via a novel microfluidic device formed in accordance with the present invention
- Figs. 10A and 10B are schematic views showing flow cytometry analysis of an experiment in which EGFP stable expressing MDAMB231 and SU-DHL-1 lymphoma cells were delivered with plasmids encoding only Cas9 protein or both sgEGFP and Cas9 protein using a novel microfluidic device formed in accordance with the present invention;
- FIGS. 10C-11D are schematic views showing further aspects of the experiment of Figs. 10A and 10B;
- Figs. 12 and 13A are schematic views showing another novel microfluidic device formed in accordance with the present invention
- Fig. 13B is a schematic view showing how plasmids encoding guide RNA and Cas9 protein can be passed into a cell using the novel microfluidic device of Figs. 12 and 13A;
- Fig. 13C is a schematic view showing further aspects of the novel microfluidic device of Figs. 12 and 13A;
- Fig. 13D is a schematic view showing a cell stress simulation of a cell being passed through the novel microfluidic device of Figs. 12 and 13A;
- Figs. 14 and 15 are schematic views showing further aspects of the novel microfluidic device of Figs. 12 and 13A;
- Fig. 16 is a schematic view showing a cell stress simulation of a cell being passed through the novel microfluidic device of Figs. 12 and 13;
- Fig. 17 is a schematic view showing further aspects of the novel microfluidic device of Figs. 12 and 13;
- Fig. 18 is a schematic view showing various cell deformation structures which may be used with the novel microfluidic device of Figs. 12 and 13A, and aspects thereof;
- Figs. 19-22 are schematic views showing how a cell slurry may be passed back and forth through the novel microfluidic device of Figs. 12 and 13A;
- Figs. 23-26 are schematic views showing further aspects of the novel microfluidic device of Figs. 12 and 13A;
- Figs. 27 and 28 are schematic views showing another novel microfluidic device formed in accordance with the present invention.
- Figs. 29A-30C are schematic views showing
- Fig. 31A is a schematic view showing another novel microfluidic device formed in accordance with the present invention.
- Figs. 31B-31D are schematic views showing further aspects of the cell deformation structures of the novel microfluidic device of Fig. 31A;
- Figs. 32A and 32B are schematic views showing the experimental results of an experiment in which 70-kDa dextran molecules and siRNA were delivered into cells using the novel microfluidic device of Fig. 31A;
- Figs. 33A and 33B are schematic views showing experimental results of an experiment in which Cas9 or Cas9/tracrRNA/crRNA complex was delivered to SK-BR-3 cells using the novel microfluidic device of Fig. 31A;
- Figs. 33C-35C are schematic views showing
- Fig. 36 is a schematic view showing flow velocity simulation of cell deformation of a cell passing through curved tunnel deformation structures of the novel microfluidic device of Fig. 31A;
- Fig. 37 is a schematic view showing experimental results of an experiment conducted to study cell recovery rates after delivery of a target molecule using the novel microfluidic device of Fig. 31A;
- Figs. 38-42 are schematic views showing
- Figs. 43-47 are schematic views showing another microfluidic device formed in accordance with the present invention.
- Figs. 48 and 49 are schematic views showing another cell deformation structure which may be utilized with the present invention.
- Figs. 50-55 are schematic views showing another microfluidic device formed in accordance with the present invention.
- a cell When a cell passes through a constriction smaller than the cell diameter, it undergoes rapid mechanical deformation, causing transient membrane disruption or holes.
- the shear and compressive forces imposed on the cell during passage through the constriction determine the degree of disruption and the size and frequency of the holes. Macromolecules small enough to pass through the holes can diffuse into the cytosol from the surrounding medium and may remain and
- the microfluidic devices of the present invention comprise a series of constrictions of different dimensions formed by structures of different shapes (Fig . 6A) .
- Microfluidic device 5 In a preferred form of the present invention, and looking now at Figs. 1A-1D, there is provided a novel microfluidic device 5.
- Microfluidic device 5 is provided.
- a base chip 10 generally comprises a base chip 10 and a cover chip 15 disposed over base chip 10.
- a plurality of structures extend between base chip 10 and cover chip 15, with cover chip 15 being spaced from base chip 10 such that a fluid (e.g., a suspension of cells) can be
- flow chamber 20 comprises an inlet 25 located at one end of flow chamber 20 and an outlet 30 located at the opposite end of flow chamber 20.
- a cell scatter zone 35 is located proximate to inlet 25 and a cell deformation zone 40 is located downstream from cell scatter zone 35, proximate to outlet 30.
- Cell scatter zone 35 comprises a plurality of cell scatter structures 45 which extend between base chip 10 and cover chip 15.
- Cell scatter structures 45 act to disperse and separate cells flowing through flow chamber 20, as will hereinafter be discussed.
- cell scatter structures 45 comprise a generally round cross-section.
- Cell deformation zone 40 comprises a plurality of cell deformation structures 50 which extend between base chip 10 and cover chip 15. Cell deformation structures 50 are spaced such that adjacent cell deformation structures 50 define a gap 55
- Gap 55 is sized such that a cell which is flowed through gap 55 is engaged by two cell deformation structures 50, whereby to mechanically constrict the cell between the cell deformation structures and momentarily mechanically deform the cell membrane, whereby to allow material (e.g., Cas9, sgRNA, etc.) to enter the cell, as will hereinafter be discussed.
- cell deformation structures 50 comprise a generally diamond-shaped cross-section.
- microfluidic device 5 is fabricated with standard polydimethylsiloxane (PDMS) microfluidics technology. Each microfluidic device 5 preferably comprises 14 identical cell-scattering zones 35 and cell
- each cell deformation zone 40 preferably contains 10 arrays of cell deformation structures 50 forming microconstrictions at gaps 55 (Fig. 1C) .
- Cell scatter zone 35 is designed to disperse or "scatter" the cell suspension.
- Cell deformation zone 40 is where cells pass through microconstrictions (i.e., gaps 55), becoming deformed and generating transient membrane holes that ensure delivery of the macromolecule ( s ) of interest.
- Interconnected channels within cell scatter zones 35 and cell deformation zones 40 enable high throughput of treated cells by preventing clogging. To optimize the microconstriction design, it is possible to provide constrictions using cell deformation
- microfluidic device 5 by flowing the cell suspension through a Tygon tube connected to inlet 25, and fluid flow was controlled by a syringe pump (not shown) .
- a syringe pump (not shown) .
- FITC fluorescein isothiocyanate
- HEK293T human embryonic kidney 293T
- microfluidic device design (Fig. 6D) was generated by arranging multiple microfluidic devices 5 side-by-side so as to demonstrate that delivery can be multiplexed.
- the cell recovery rate after delivery for both HEK293T and SUM159 cell lines was close to 100% (Fig. 6E) .
- cells are passed through microconstrictions (i.e., gaps 55) formed by diamond- patterned cell deformation structures 50 at a flow rate of 30 ⁇ /min.
- Cell stress simulation (Fig. ID and Fig. 7) and flow velocity simulation (Fig.
- the novel microfluidic device 5 of the present invention can be used to successfully deliver plasmids encoding different sgRNAs and Cas9 into different types of cells and achieve precise genome editing and perform specific gene loss-of-function analysis, as depicted in Fig. IB.
- cell deformation structures 50 comprise
- constriction depth was 15 pm, and the width of gap 55 varied from 4 to 5 pm (Fig. 1C) .
- a series of testing deliveries of FITC-labeled ssDNA into HEK293T cells were performed (Fig. 2A) .
- siRNA delivery for gene knockdown was tested. Considering both delivery efficiency and cell viability, a microconstriction (i.e., a gap 55) having a width of 4 pm, a fluid flow rate of 250 ⁇ /min through flow chamber 20, and single passage of the cells through microfluidic device 5 was chosen for all subsequent experiments.
- a microconstriction i.e., a gap 55
- a fluid flow rate 250 ⁇ /min through flow chamber 20
- single passage of the cells through microfluidic device 5 was chosen for all subsequent experiments.
- three siRNAs specific for Aktl were delivered into PC-3 cells, all of the oligos achieved >70% knockdown efficiency in 48 hours after delivery (Fig. 2D) .
- depletion of Aktl by all three siRNAs suppressed cell growth, which is consistent with previous research (Fig. 2E),
- GFP green fluorescent protein
- the method and apparatus of the present invention achieved even higher efficiency than FuGENE HD transfection in human anaplastic large cell lymphoma cells and mouse embryonic stem cells without inducing stem cell differentiation (Fig. 2F and Fig.
- microfluidic device 5 may be optimized for different cell types, so that further improvement can be
- microfluidic device 5 is modified for use with different cell types, with the goal of establishing cell-specific delivery protocols.
- the various parameters of microfluidic device 5 e.g., the relative spacing, shape and configuration of cell deformation structures 50 and/or cell scatter structures 45, the width of gap 55, etc.
- EGFP enhanced GFP
- EGFP was introduced into cells with lentivirus, and the EGFP encoding sequences were integrated into chromosomal DNA. Plasmids encoding Cas9 only or sgRNAs targeting EGFP (sgEGFP-1 and sgEGFP-2) and Cas9 were delivered into adherent MDA- MB-231 cells and non-adherent SU-DHL-1 lymphoma cells. To enhance delivery efficiency, cells were passed through the same microfluidic device 5 three times. After delivery, cells were allowed to recover in culture for 7 days. Bright-field and fluorescence microscopic (Fig. 3A) and flow cytometric analyses (Fig. 3B and Fig. 10A) showed that plasmid delivery was efficient and genome editing was successful in MDA-MB-231 cells, achieving >90% EGFP knockout
- apparatus of the present invention could be used for gene disruption and function analysis, furthermore
- Surveyor mutation detection assay revealed substantial cleavage at the AAVS1 locus, with indels occurring at a frequency of about 18 to 46% when delivery was optimized by passage of the cells through microfluidic device 5 three times (Fig. 4B) .
- Plasmids encoding Cas9 and sgRNA targeting NUAK2 were delivered into HeLa cells via the membrane deformation method provided by microfluidic device 5, and the cells were allowed to recover in culture for 7 days.
- Mutation detection assay revealed substantial cleavage at the NUAK2 gene locus, with indels occurring at a frequency of about 30% (Fig. 4E) .
- the indel mutation frequencies could be optimized in a few ways such as by passing cells multiple times through the
- microfluidic device 5 increasing the concentration of the plasmids, and/or by using a selective drug to kill the nontransfected cells.
- Plasmids encoding Cas9 and sgRNA targeting phosphatase and tensin homolog (Pten) were delivered into MCF7 cells using microfluidic device 5, followed by culture for 48 hours and puromycin selection. More than 80% of the cells survived the selection process, indicating the high delivery efficiency of
- FIG. 5A Cells were immunostained to further confirm successful knockout of Pten and Akt activation (Fig. 11B) . Cell proliferation was also increased in MCF7 cells after Pten knockout (Fig. 5B) , which is consistent with a previous study. See J. Zhang, P. Zhang, Y. Wei, H. L. Piao, W. Wang, S. Maddika, M. Wang, D. Chen, Y. Sun, M. C. Hung, J. Chen, L. Ma, Deubiquitylation and stabilization of PTEN by USP13.
- Tumor suppressor p53 binding protein 1 (53BP1) is required for DNA damage response and tumor
- microfluidic device 5 is a rapid, efficient, and high- throughput method for CRISPR-Cas9-mediated genome editing and gene knockout analysis and may provide a multiplexable and integrated platform for gene
- the present invention uses the mechanical
- the novel method and apparatus of the present invention also have the potential to deliver other materials into the cell, such as proteins and nanoparticles .
- the novel method and apparatus of the present invention can be applied across different types of cells, including hard-to-transfect cells, such as immune cells and stem cells, to address clinical needs. By analyzing the specific deformations experienced by different types of cells passing through a microconstriction, device parameters can be optimized to achieve excellent performance with a wide range of cell types and applications.
- the mechanical deformability-based principle used with the novel apparatus of the present invention provides a new solution for delivery and has
- the novel method and apparatus of the present invention do not rely on cell type or the structure of the target molecule; however, the present invention is easier to use with higher throughput than microinjection. See Y. Zhang, L. C. Yu,
- Electroporation has been successfully applied to CRISPR-Cas9 delivery and allows highly efficient RNA-guided genome editing. However, unlike the microfluidic method of delivery utilized in the present invention, electroporation damages cells and often affects cell viability. The high delivery efficiency and associated high cell viability achieved using the novel method and
- apparatus of the present invention facilitates efficient genome editing and precise gene functional analysis.
- the cells may be passed multiple times through
- the concentration of the plasmids may be increased, and/or a selective drug may be used to kill the nontransfected cells.
- a selective drug may be used to kill the nontransfected cells.
- Using stable Cas9-expressing cells for sgRNA delivery or Cas9 protein/ sgRNA co-complexes may also be helpful to increase the indel frequencies.
- microfluidics-based platforms such as the present invention as a basic research tool has the advantage that it is capable of integration and incorporation into a larger system including multiple posttreatment modules.
- This enables potential integration of our CRISPR-Cas9 system delivery and gene loss-of-function or mutation correlation analysis.
- microfluidic device 5 could be integrated with a single-cell protrusion microfluidic chip for screening genes potentially involved in cell protrusion mechanics. See K. Zhang, C. K. Chou, X. Xia, M. C. Hung, L. Qin, Block-Cell-Printing for live single-cell printing. Proc. Natl. Acad. Sci . U.S.A. Ill, 2948-2953 (2014) .
- Use of the novel methods and apparatus of the present invention would generate large quantities of CRISPR-Cas9-mediated knockout or knockin cells for high throughput cell phenotypic screening .
- the present invention enables novel approaches to this type of gene therapy.
- high delivery efficiency has been achieved compared with traditional liposome-mediated delivery in SUDHL-1 lymphoma cells, and successful application in anaplastic large cell lymphoma cells provides the possibility of delivery in primary patient cells.
- a patient's target cells could be isolated from blood or other tissue, treated with the novel method and apparatus of the present invention to deliver the CRISPR-Cas9 knockin system with wild-type template to correct the disease gene mutation, and then reintroduced into the patient.
- the enhanced delivery efficiency provided by the present invention would increase the likelihood of correcting disease mutation genes by gene targeting therapy.
- SPR 220-7 photoresist was purchased from Rohm and Haas Electronic Materials.
- PDMS (GE 615 RTV) was purchased from Fisher Scientific.
- Tygon tubing was purchased from Saint-Gobain .
- Flat steel pins were purchased from New England Small Tube.
- Fetal bovine serum (FBS), trypsin, and penicillin-streptomycin were purchased from Fisher Scientific.
- Dulbecco's modified Eagle's medium (DMEM) Ham's F-12 medium, RPMI 1640 and F-12K medium, insulin, hydrocortisone, and
- PBS phosphate-buffered saline
- SiRNAs targeting Aktl were used previously and purchased from Sigma-Aldrich.
- Plasmids encoding sgRNA and Cas9 were purchased from Addgene, and specific sgRNA target sequences were cloned into the CRISPR v2 vector (Addgene plasmid #52961) .
- the 20-bp target sequences of the indicated sgRNAs were as follows: sgEGFP-1,
- GGGCGAGGAGCTGTTCACCG GGGCGAGGAGCTGTTCACCG
- sgEGFP-2 GAGCTGGACGGCGACGTAAA
- sgAAVSl GGGGCCACTAGGGACAGGAT
- sgNUAK2 GGGCGAGGAGCTGTTCACCG
- telomere length TTGATCAGCCCTTCCGCCAG; sgPten, AGATCGTTAGCAGAAACAAA; sg53BPl, CATAATTTATCATCCACGTC .
- the primers used for PCR amplification of sgRNA target regions were as follows: EGFP-FP, ATGGTGAGCAAGGGCGAGGA; EGFP-RP,
- TTACTTGTACAGCTCGTCCA AAVS1-FP, CCCCGTTCTCCTGTGGATTC ; AAVS1-RP, ATCCTCTCTGGCTCCATCGT; NUAK2-FP,
- microchip pattern of microfluidic device 5 was designed with AutoCAD (Autodesk) .
- microfluidic device 5 consists of 14 identical cell- scatter zones 35 and cell deformation zones 40, and each cell deformation zone contains 10 arrays of constrictions (i.e., cell deformation structures 50) .
- the constriction depth i.e., the distance between base chip 10 and cover chip 15
- the parallel chip design was generated by arranging multiple microfluidic devices 5 side-by-side.
- Microfluidic device 5 was fabricated using standard
- the negative photoresist SU8-3025 (MicroChem) was used to fabricate patterns on a silicon wafer.
- the silicon wafer was then silanized using trimethylchlorosilane (Thermo Scientific) for 30 min to facilitate PDMS mold release.
- PDMS prepolymer (10A:1B, Sylgard 184 silicone elastomer kit, Dow Corning) was poured onto the silicon wafer and cured at 80°C for 1 hour. Holes were then punched in the PDMS for the inlets 25 and outlets 30, and oxygen plasma treatment was used to chemically bond the PDMS mold (the base chip) to a glass slide (the cover chip) .
- the stress on the cell was computed as the von Mises stress, which is a scalar value determined from the stress tensor of a particle under the pressure in fluid flow.
- HEK293T, MCF7 , MDA-MB-231, and HeLa cells were grown in DMEM supplemented with 10% FBS and 1%
- PC-3 cells were grown in F-12K medium supplemented with 10% FBS and 1% penicillin- streptomycin.
- SUM159 cells were grown in Ham's F-12 medium supplemented with 5% FBS, 1% penicillin- streptomycin, insulin (5 pg/ml), and hydrocortisone (1 pg/ml) .
- Human SU-DHL-1 anaplastic large cell lymphoma cells were cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin-streptomycin.
- Mouse AB2.2 embryonic stem cells were maintained on a 0.1% gelatin ( Sigma-Aldrich) -coated tissue culture dish in high- glucose DMEM, supplemented with 15% FBS, 55 ⁇ ⁇ - mercaptoethanol (Life Technologies), and 0.01% mouse leukemia inhibitory factor (Millipore) under feeder- free conditions.
- microfluidic device 5 The channels in microfluidic device 5 were wetted with PBS and blocked with 1% bovine serum albumin in PBS for 10 min.
- Cells were first suspended in the desired volume of Opti-MEM medium (Life Technologies) and then mixed with the desired amount of delivery material (ssDNA, siRNA, or plasmid) and loaded into plastic Tygon tubing with a 5-ml syringe. The tubing was then connected to inlet 25 of microfluidic device 5 by a flat steel pin.
- a syringe pump controlled the fluid flow through flow chamber 20 of microfluidic device 5. Treated cells were incubated in a 37°C incubator for 20 min to recover before further treatment.
- Plasmids encoding both Cas9 and sgRNA targeting Pten or 53BP1 were delivered into MCF7 or HeLa cells, respectively, via microfluidic device 5. After 48 hours of culture, the cells were grown in DMEM
- Texas red-conjugated goat anti- rabbit T-2767, Life Technologies
- sgRNACas9-mediated knockout cells were allowed to recover in culture for 2 or 7 days, respectively.
- the primary antibodies used were anti- Aktl (ab32505, Abeam), anti-53BPl (ab21083, Abeam), and anti-actin (A3853, Sigma-Aldrich) .
- Aktl Aktl
- anti-53BPl ab21083, Abeam
- anti-actin A3853, Sigma-Aldrich
- Genomic DNA was extracted using the PureLink Genomic DNA Mini Kit (K1820-00, Life Technologies) according to the manufacturer's instructions. PCR amplicons of nuclease target sites were generated and analyzed for the presence of mismatch mutations using the Transgenomic Surveyor Mutation Detection Kit
- PCR amplicons of sgRNA target regions were denatured by heating for 10 min at 95°C, annealed to form heteroduplex DNA using a thermocycler from 95°C to 25°C at -0.3°C/s, digested with Surveyor Nuclease S for 2 hours at 42°C, and separated by 1% agarose gel electrophoresis.
- PCR products corresponding to genomic modifications were cloned into pCR4-TOPO vector using the TOPO TA Cloning Kit (Life
- cells (5 ⁇ 10 4 ) were seeded in 60-mm dishes in complete medium and cultured for 7 days. Cells were harvested by trypsinization daily and counted in a Countess II FL Automated Cell Counter (Life Technologies) .
- CPT sensitivity was assessed by colony survival assay. Briefly, CPT-treated cells (500 to 1000) were plated in 60-mm dishes in complete medium and incubated for 2 to 3 weeks to form clones. Clones were stained with Coomassie blue, and survival rate was calculated.
- CRISPR-Cas9 technology is a powerful tool for genome editing in both research and therapeutics such as induced pluripotent stem cell applications and cancer immune therapy.
- the ability to deliver sgRNA and Cas9 in a variety of cell types, particularly hard-to-transfect cells with both high delivery efficiency and high cell viability, is critical in therapeutic and research applications.
- microfluidic device 5 a single time may not result in a sufficient number of cells being transfected (e.g., having the Cas9-sgRNA passed into the cell),
- the cells to be transfected are hard-to-transfect cells, e.g., lymphoma cells and embryonic stem cells.
- hard-to-transfect cells e.g., lymphoma cells and embryonic stem cells.
- the present invention provides an optimized microfluidic approach to deliver plasmids encoding sgRNA and Cas9 efficiently into human cells, including difficult-to-transfect cells, such as nonadherent lymphoma cells. More particularly, in another form of the present invention, there is provided a more efficient and portable CRIPSR-Cas9 microfluidic device 105 (sometimes referred to as a "Back and Forth Chip”) which can enable new avenues of biomedical research and gene-targeting therapy.
- microfluidic device 105 is generally similar to the microfluidic device 5 discussed above, however, microfluidic device 105 is configured for repeated passage of a cell slurry through the flow chamber in a first direction, and then in a second, opposite direction, as will hereinafter be discussed in further detail.
- Microfluidic device 105 generally comprises a base chip 110 and a cover chip 115 (Fig. 13A) disposed over base chip 110.
- a plurality of structures extend between base chip 110 and cover chip 115, with cover chip 115 being spaced from base chip 110 such that a fluid (e.g., a suspension of cells) can be selectively passed through a flow chamber 120 located between base chip 110 and cover chip 115, as will hereinafter be discussed in further detail.
- a fluid e.g., a suspension of cells
- flow chamber 120 comprises a first port 125 located at one end of flow chamber 120 and a second port 130 located at the opposite end of flow chamber 120.
- Flow chamber 120 comprises a plurality of cell scatter zones 135 and a plurality of cell deformation zones 140 located between adjacent cell scatter zones 135.
- Each cell scatter zone 135 comprises a plurality of cell scatter structures 145 which extend between base chip 110 and cover chip 115.
- Cell scatter structures 145 act to disperse and separate cells flowing through flow chamber 120, as will hereinafter be discussed.
- cell scatter structures 145 comprise a generally round cross-section.
- Each cell deformation zone 140 comprises a plurality of cell deformation structures 150 which extend between base chip 110 and cover chip 115.
- Cell deformation structures 150 are spaced such that adjacent cell deformation structures 150 define a gap 155 (Fig. 13A) therebetween.
- Gap 155 is sized such that a cell which is flowed through gap 155 engages two cell deformation structures 150, whereby to mechanically constrict the cell between the cell deformation structures and momentarily mechanically deform the cell membrane, whereby to allow material (e.g., Cas9, sgRNA, etc.) to enter the cell, as will hereinafter be discussed.
- cell deformation structures 150 comprise a generally diamond-shaped cross-section.
- the CRISPR-Cas9 microfluidic device 5 generally comprises first port 125 and second port 130 separated by flow chamber 120.
- Flow chamber 120 comprises at least one cell deformation zone 140, wherein the at least one cell deformation zone 140 has a plurality of spaced cell deformation structures 150 between which cells must pass, and wherein the spacing between the cell deformation structures is such that deformation of the cells is required in order for the cells to pass between the cell deformation structures.
- Flow chamber 120 preferably also comprises at least one cell scatter zone 135, wherein the at least one cell scatter zone comprises a plurality of spaced cell scatter structures 145 between which the cells must pass, and wherein the spacing between the cell scatter structures is such that the cells are dispersed as they pass between the cell scatter structures.
- flow chamber 120 comprises a plurality of cell deformation zones 140 and a plurality of cell scatter zones 135.
- a first syringe 160 and a second syringe 165 are attached to first port 125 and second port 130, respectively.
- At least one of the syringes contains a mixture of target cells and the material which is to be inserted into the target cells.
- the first and second syringes are then used to pass the mixture back and forth through flow chamber 120, with the target cells passing through the at least one cell deformation zone 140 (and, where flow chamber 120 comprises at least one cell scatter zone 135, through the at least one cell scatter zone) . In this way, each target cell is subjected to repetitive
- first syringe 160 preferably comprises a suspension of target cells
- second syringe 165 preferably comprises the material which is to be inserted into the target cells.
- First syringe 160 and second syringe 165 are then used to insert their contents into flow chamber 120 so that the contents mix, and then the first and second syringes are worked in opposing directions (Fig. 19) so as to repeatedly cycle the mixture through the at least one cell deformation zone 140 (and, where flow chamber 120 comprises at least one cell scatter zone 135, through the at least one cell scatter zone) .
- each target cell is
- one or both of the first and second syringes may be replaced by alternative fluid delivery mechanisms (e.g., a pump, an elastic reservoir, a pipette, a vacuum, mechanical, electronic, heat, magnetic or optically-powered pushing or pulling equipment, etc.) .
- alternative fluid delivery mechanisms e.g., a pump, an elastic reservoir, a pipette, a vacuum, mechanical, electronic, heat, magnetic or optically-powered pushing or pulling equipment, etc.
- microfluidic device 105 may comprise a single port through which the target cells, and the material which is to be inserted into the target cells, is delivered into flow chamber 120.
- a single syringe (or other fluid delivery mechanism) may both insert and remove the target cells, and the material which is to be inserted into the target cells, to/from flow chamber 120.
- microfluidic device 105 may be configured such that flow chamber 120 comprises a compound flow path, whereby to introduce turbulence into the cell slurry and better separate cells as they pass through cell deformation zone 140.
- inlet 125 may be fluidically connected to a plurality of entrances 170 which open onto flow chamber 120 at different
- the present invention provides numerous advantages
- the present invention provides high-delivery efficiency of different macromolecules into different cell types, including hard-to-transfect lymphoma cells and embryonic stem cells, while maintaining high cell viability;
- the "back and forth” chip allows the target cells to be “squeezed” (for increased transfection) as many times as desired, by simply varying the number of times that the target cells are passed through the flow chamber;
- the present invention provides highly- efficient genome editing and successful generation of specific gene-knockout cell lines by delivering plasmids encoding different sgRNAs and Cas9 into human cell lines, including nonadherent lymphoma cells - this sgRNA and Cas9 delivery method facilitates gene mutation correlation and gene therapy across different cell types, particularly difficult-to-transfect cell types which potentially enables many research and clinical applications;
- the method of the present invention has the advantage of high throughput delivery of almost any macromolecule into almost any cell type - microfluidic platforms have the potential to serve as a broad-based universal delivery platform and provide the advantages of precise control over treatment conditions at the single-cell level with macro-scale throughput. 5 Cas9 Ribonucleoprotein Delivery Via
- CRISPR palindromic repeats
- sgRNA single-guide RNA directs the Cas9 nuclease to generate site-specific double-strand breaks (DSBs) for targeted gene
- T-cell genome editing holds great promise for immunotherapies for cancer, HIV, primary immune deficiencies, and autoimmune diseases, but genetic manipulation of human T cells with high efficency has been challenging.
- Cas9 and sgRNA can be encoded within the plasmid DNA of viral or nonviral vectors for delivery into cells.
- plasmid-mediated delivery can result in the uncontrolled integration of the DNA sequence into the host genome and unwanted immune responses. See H. Hemmi, 0. Takeuchi, T.
- Cas9/sgRNA ribonucleoprotein (RNP) complex for delivery provides an alternative means of reducing off-target effects and avoiding unwanted plasmid integration. Electroporation of Cas9 RNPs has been achieved for efficient genome editing in
- a novel microfluidic device uses physical constrictions to deform and shear cells to generate transient membrane holes that facilitate passive diffusion of delivery materials into the cytosol in a similar manner to the novel microfluidic devices 5, 105 discussed above.
- the present invention achieves efficient and precise genome editing with reduced off-target effects by the delivery of Cas9 RNPs into cells.
- microfluidic cell deformation-based Cas9 RNP delivery provides a plasmid-free and transfection reagent-free method for use in different cell types, particularly in hard-to- transfect cells.
- novel method and apparatus of the present invention can facilitate Cas9 RNP-directed genome editing and support the
- novel membrane deformation-based microfluidic devices of the present invention have the advantage of high- throughput delivery of almost any macromolecule into almost any cell type. See X. Han, Z. Liu, M. C. Jo, K. Zhang, Y. Li, Z. Zeng, N. Li, Y. Zu, L. Qin, Sci Adv 2015, 1, el500454; and A. Sharei, J. Zoldan, A.
- microfluidic devices 5, 105 can be used to successfully deliver plasmids encoding Cas9 and sgRNA into different cell types and to achieve efficient genome editing.
- Fig. 31A there is shown another novel microfluidic device 205 formed in accordance with the present invention. Novel
- microfluidic device 205 is generally similar to the aforementioned microfluidic devices 5, 105, however, microfluidic device 205 has been optimized for
- microfluidic device 205 has been optimized based on the principle that rapid mechanical deformation of the cell causes transient membrane disruption or holes that facilitate the passive diffusion of material into the cell cytosol. See A. Sharei, J. Zoldan, A. Adamo, W. Y.
- constriction design i.e., the arrangement and shape of cell deformation structures 50, 150
- dimensions i.e., the size of cell deformation structures 50, 150 and the width of gaps 55, 15
- microfluidic device 205 the
- constriction shape i.e., the shape of the gap between adjacent cell deformation structures
- microfluidic device 205 generally comprises a base chip 210 and a cover chip 215 disposed over, and spaced from, base chip 210, whereby to define a flow chamber 220 therebetween.
- An inlet 225 is fluidically connected to one end of flow chamber 220 and an outlet 230 is fluidically connected to the opposite end of flow chamber 220 such that a cell slurry may be flowed from inlet 225, through flow chamber 220 to outlet 230, as will hereinafter be discussed.
- Flow chamber 220 generally comprises one or more cell scatter zones 235 and one or more cell
- cell scatter structures 245 comprise a plurality of cell scatter structures 245 extending between base chip 210 and cover chip 215.
- cell scatter structures 245 comprise a generally circular cross-section.
- Cell deformation zones 240 comprise a plurality of cell deformation structures 250.
- Cell deformation structures 250 preferably comprise an "X"- shaped (or “star shaped") cross-section (see Fig. 31B) and are arranged such that adjacent cell deformation structures 250 define a curved tunnel 255
- a slurry of cells is introduced into inlet 225 (e.g., using a syringe pump), whereby to enter flow chamber 220.
- the slurry of cells flows through one or more cell scatter zones 235, contacting cell scatter structures 245, whereby to better
- the cells then enter one or more cell deformation zones 240 and an individual cell is drawn into each curved tunnel 255 between adjacent cell deformation structures 250, whereby to momentarily mechanically deform the cell, causing transient membrane disruption that facilitates passive diffusion of material into the cell cytosol.
- material (s) which is to be passed into the cell e.g., Cas9 RNP
- Microfluidic device 205 is preferably fabricated with standard polydimethylsiloxane (PDMS)
- each chip comprises 10 cell deformation zones 240 that form
- microconstrictions i.e., curved tunnels 255 .
- cell deformation structures 250 were arranged horizontally and
- Fig. 31C curved tunnels 255
- suspended cells were applied to microfluidic device 205 through Tygon® tubing connected to inlet 225, and fluid flow was controlled by a syringe pump (not shown) .
- a series of test deliveries of fluorescein isothiocyanate (FITC)- labeled 70-kDa dextran molecules into human luminal- like SK-BR-3 breast cancer cells were performed.
- FITC fluorescein isothiocyanate
- constriction width i.e., the width of curved tunnels 255
- fluid flow rates were chosen based on previous experiments.
- constriction width of curved tunnel 255 varied from 4 pm to 8 pm and the flow rate was set at 150 ⁇ /min.
- the delivery efficiency and cell viability were calculated for different structure arrangements, forming various arrangements of curved tunnels 255 in arrays 1-4 (Fig. 31D) .
- the delivery efficiency of 70- kDa dextran varied from about 60%-70% in the array 1-4 designs.
- the number of cell deformation zones 240 disposed along flow chamber 220 was increased to 10 in order to attain greater than 90% delivery efficiency of 70-kDa dextran (Fig. 31D) .
- the cell recovery rates after delivery exceeded 90% for all of the designs (Fig. 37) .
- higher delivery efficiency was often accompanied by lower cell viability using the
- fluorescent labeled dextran molecules and short interfering RNAs were selected to simulate protein and RNA delivery.
- Adherent SK-BR-3 and non-adherent neutrophil-like HL-60 cells were initially chosen to assess the delivery ability of the chip across
- FITC-labeled 70-kDa dextran molecules or siRNAs were delivered separately into the two cell lines with an efficiency greater than 90%
- microfluidic device 205 has the potential to solve problems related to the use of cells that are difficult to transfect.
- Primary T cells the well-known, hard-to-transfect cells, were chosen for the delivery tests. Because primary T cells are less than 10 pm in size, the constriction width of curved tunnel 255 was varied from 2 pm to 4 pm. Even in the hard-to-transfect primary T cells, greater than 80% delivery efficiency was achieved for dextran and 90% delivery efficiency was achieved for siRNA (Fig. 32A and Figs. 38 and 39) .
- Figs. 32A and 32B The efficiency of the co-delivery of dextran and siRNA was greater than 70% (Figs. 32A and 32B) , indicating successful application of the present invention with hard-to-transfect cells. It will be appreciated that the delivery parameters of the present invention may be optimized to improve the delivery performance with respect to other specific cell types.
- tracrRNA Alt-R CRISPR transactivating RNA
- crRNA system for Cas9 RNP assembly and delivery
- crRNA tracrRNA complex. See E. Deltcheva, K.
- the crRNA was designed to target a sequence within enhanced green fluorescent protein (EGFP) , and the recombinant Cas9 protein was fused with nuclear-localization signals (NLSs) and purified following overexpression in Escherichia
- Cas9 /tracrRNA/crRNA complex was active in vitro by cleavage of a plasmid encoding EGFP (Fig. 40) .
- SK-BR- 3 cells stably expressing EGFP were then used to demonstrate the Cas9 RNP delivery and genome editing ability of microfluidic device 205.
- the Cas9 RNP complex was delivered into cells for 3 days and flow cytometric analyses were used to determine the knockout efficiency of EGFP (Fig. 33A) .
- the delivery of Cas9 RNP-induced EGFP expression was abolished in a protein and RNA concentration-dependent manner.
- the CRISPR-Cas9 system can induce off-target mutations at sites that are highly homologous to on- target sites and cause unwanted chromosomal
- Cas9 RNP delivery has the advantage to reduce off-target effects compared with plasmid transfection for genome editing. See S. Kim, D. Kim, S. W. Cho, J. Kim, J. S. Kim, Genome Res 2014, 24, 1012-1019; and S.
- microfluidic device 205 were drastically lower than those treated with plasmid transfection, whereas the on-target mutation frequencies were comparable between the two groups.
- the ratio of on- to off-target activities was 6.3-fold (53.7/8.5) higher for p38 RNP delivery by microfluidic device 205 versus plasmid transfection, which indicated that chip-mediated Cas9 RNP delivery using microfluidic device 205 was an efficient and precise genome editing method (Figs. 34A and 34B) .
- RNP delivery did not sacrifice genome-editing activities at on-target sites, while reducing off-target effects, which greatly benefits the application of CRISPR technology for therapeutic genome editing.
- human CD4+ T cells were chosen to investigate whether chip-mediated Cas9 RNP delivery using microfluidic device 205 could improve genome editing in these hard-to-transfect cells.
- Cas9 RNP and homologous donor DNA were co-delivered into human CD4+ T cells using microfluidic device 205 to test the knock-in genome modification frequency.
- the crRNA and homology-directed repair (HDR) template containing a novel Hindlll restriction enzyme cleavage site was designed to target the PD-1 (PDCD-1) locus (Fig. 35A) .
- PD-1 is a trans-membrane receptor found on the surface of T cells that negatively regulates immune responses by preventing the activation of T cells. See D. M. Pardoll, Nat Rev Cancer 2012, 12, 252-264. PD-1 inhibitors are approved for the treatment of
- PD-1 Cas9 RNPs co-delivered with the HDR template using microfluidic device 205
- PD-1 in the presence of both PD-1 Cas9 RNP and the PD- 1 HDR template, which indicated HDR-mediated knock-in genome modifications were achieved in human primary CD4+ T cells using the method and apparatus of the present invention (Fig. 35C) .
- microfluidic cell deformation-based Cas9 RNP delivery provided efficient and precise genome editing in primary T cells, which holds great promise for therapeutic T- cell engineering and applications such as the
- SPR 220-7 photoresist was purchased from Rohm and Haas Electronic Materials.
- PDMS (GE 615 RTV) was purchased from Fisher Scientific.
- Tygon tubing was purchased from Saint-Gobain .
- Flat steel pins were purchased from New England Small Tube.
- Fetal bovine serum (FBS), trypsin, and penicillin-streptomycin were purchased from Fisher Scientific.
- Dulbecco's modified Eagle's medium (DMEM) Ham's F-12 medium, RPMI-1640, Iscove's Modified Dulbecco's Medium (IMDM) and McCoy's
- the single-stranded oligonucleotides of PD-1 HDR template were synthesized from Integrated DNA Technologies.
- the 20-bp target sequences of the indicated CRISPR crRNA were as follows: EGFP,
- GGGCGAGGAGCTGTTCACCG p38, AGGAGAGGCCCACGTTCTAC ; PD-1, CGACTGGCCAGGGCGCCTGT .
- the 20-bp off-target sequences of guide RNA targeting p38 were AGGGGAGACCCAGGATCTAC .
- the primers used for PCR amplification of target regions were as follows: p38-FP, AGTCTGCGGGGTCGCGG; p38-RP, CACACAGAGCCATAGGCGCC; p38-off-target-FP,
- microfluidic device 205 was designed with AutoCAD (Autodesk) .
- Each cell deformation zone 240 of each microfluidic device 205 preferably comprises 10 arrays of structures (i.e., cell deformation structures 250) forming curved tunnel cell passages (i.e., curved tunnels 255) .
- the final design of microfluidic device 205 preferably comprises 10 repeats of identical cell deformation zones 240.
- the constriction width of curved tunnel 255 preferably varies from 4 pm to 8 pm for SK-BR-3, HL-60, MDA-MB-
- Microfluidic device 205 was fabricated according to standard photolithography and soft lithography procedures.
- PDMS polydimethylsiloxane
- SK-BR-3 cells were grown in McCoy's 5a Medium supplemented with 10% FBS and 1% penicillin- streptomycin in a humidified atmosphere of 5% C02/95% air at 37°C.
- HL-60 cells were cultured in IMDM with FBS to a final concentration of 20%.
- MDA-MB-231 cells were grown in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin.
- SUM159 cells were grown in Ham's F-12 medium supplemented with 5% FBS, 1%
- penicillin-streptomycin penicillin-streptomycin, insulin (5 mg/ml), and hydrocortisone (1 mg/ml) .
- Human CD4+ T-cells were purchased from PRECISION FOR MEDICINE (negatively selected, 12812) .
- the T cells were activated in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin/streptomycin, Hepes (5 mmol/L), Glutamax (2 mmol/L), 2-mercaptoethanol (50 ⁇ /L), nonessential amino acids (5 mmol/L) and sodium pyruvate (5 mmol/L) .
- the medium was supplemented with 40 IU/mL IL-2.
- the primary CD4+ T cells were pre-activated on CD3 (UCHT1; BD Pharmingen) and CD28 (CD28.2; BD Pharmingen) coated plates for 48 h.
- Plates were coated with 10 g/mL CD3 and CD28 in PBS for at least 2 h at 37 °C.
- Cas9 RNP assembly the Alt-R CRISPR-Cas9 System (Integrated DNA Technologies) was used, which consists of Alt-R S.p. Cas9 Nuclease 3NLS combined with Alt-R CRISPR crRNA and tracrRNA. The crRNA and tracrRNA were suspended in Nuclease-Free Duplex Buffer and mixed equally to a final duplex concentration (for example, 1 ⁇ ) . The two RNA oligos mixture was heated at 95 °C for 5 min and then allowed to cool to room temperature (20-25 °C) .
- Alt-R CRISPR-Cas9 System Integrated DNA Technologies
- Cas9 Nuclease 3NLS combined with Alt-R CRISPR crRNA and tracrRNA.
- the crRNA and tracrRNA were suspended in Nuclease-Free Duplex Buffer and mixed equally to a final duplex concentration (for example, 1 ⁇ ) .
- the two RNA oligos mixture was heated at 95 °C for 5 min
- the Cas9 nuclease was diluted in Opti-MEM medium (Life Technologies) to a working concentration (for example, 1 ⁇ ) and incubated with complexed crRNA : tracrRNA oligos at room temperature for 5 min to assemble the RNP complexes.
- Flow chamber 220 of microfluidic device 205 were wetted with PBS and blocked with 1% bovine serum albumin (BSA) in PBS for 10 min.
- BSA bovine serum albumin
- Cells were first suspended in the desired volume of Opti-MEM medium and then mixed with amount of Cas9 RNP complexes and loaded into a plastic Tygon tube with a 5-mL syringe.
- the tube was connected to inlet 225 by a flat steel pin.
- a syringe pump controlled the rate of the fluid flow through
- microfluidic device 205 Treated cells were incubated in a 37°C incubator for 20 min to recover before further treatment .
- Flow cytometric analysis was conducted after EGFP Cas9 RNP-mediated knockout - cells were allowed to recover in culture for 3 days, followed by analysis of EGFP fluorescence with a BD LSRFortessa cell analyzer. Cell-surface staining was performed with PD- 1-PE (EH12.2H7; Biolegend) for 15 min on ice. Cells were kept at 4 °C throughout the staining procedure until cell sorting to minimize antibody-mediated
- Genomic DNA was extracted using the PureLink Genomic DNA Mini Kit (K1820-00, Life Technologies) according to the manufacturer's instructions. PCR amplicons of nuclease target sites were generated and analyzed for the presence of mismatch mutations using the Transgenomic Surveyor Mutation Detection Kit
- PCR amplicons of sgRNA target regions were denatured by heating for 10 min at 95°C, annealed to form heteroduplex DNA using a thermocycler from 95° to 25°C at -0.3°C/s, digested with Surveyor Nuclease S for 2 hours at 42°C, and separated by 1% agarose gel electrophoresis.
- PCR products corresponding to genomic modifications were cloned into pCR4-T0P0 vector using the TOPO TA Cloning Kit (Life
- the HDR templates for PD-1 are single-stranded oligonucleotides complementary (antisense strand) to the target sequence and contain a Hindiii restriction sequence along with 90-nt homology arms.
- the PD-1 HDR template additionally causes a frameshift and nonsense mutation by replacing 12 nt with 11 nt .
- PD-1 HDR template is 5 ' -AAC CTG ACC
- the targeted region was amplified by PCR.
- the PCR products were purified and then digested by the enzyme Hindlll for 2h at 37 °C.
- the product was resolved on 1.5% agarose gel. The percentage of HDR was calculated using the
- novel microfluidic device 5 comprises a cell deformation zone 40 disposed within a flow chamber 20.
- Cell deformation zone 40 comprises a plurality of cell deformation structures 50 which are spaced such that adjacent cell deformation structures
- Gap 55 is sized such that a cell which is flowed through gap 55 engages the cell deformation structures 50, whereby to
- Novel microfluidic devices 105 and 205 (with cell deformation zones 140 and 240, respectively; flow chambers 120 and 220, respectively; cell deformation structures 150, 250, respectively; and gap 155 and curved tunnel 255, respectively) utilize similar concepts . However, it has been found that it can be
- HSCs human hematopoietic stem cells
- Microfluidic device 305 is generally similar to the aforementioned microfluidic devices 5, 105 and 205, except that in this form of the invention, deformation structures 50, 150 and/or 250 are replaced by novel deformation structures 350, and cell deformation zones 40, 140 and 240 have been modified, as will hereinafter be
- deformation structures 350 generally comprise an "inverted funnel" shape comprising a base portion 352 and a riser portion 353.
- deformation structures 350 are
- deformation zone 340 differs from the aforementioned deformation zones 40, 140 and 240 in that the flow chambers 20, 120 and 240 have been replaced by a plurality of flow channels 342, with each flow channel being defined by an uninterrupted side wall 343 disposed on one side of the flow channel and a side wall 344 comprising at least one deformation structure 350 extending along the other side of the flow channel. Side walls 343 and 344 of flow channels 342 are spaced apart, and cell deformation structures 350 are sized, such that gaps 355 are optimized for the physical
- the target cell e.g, for the human hematopoietic stem cell, a gap preferably of
- a cell e.g., a human hematopoietic stem cell
- a cell e.g., a human hematopoietic stem cell
- the cell will contact the edge of riser portion 353 of a deformation structure 350 (Figs. 45 and 47) and squeeze through the gap 355 between the deformation structure and the opposing side wall of the flow channel, whereby to momentarily mechanically deform the cell membrane of the cell and allow
- microfluidic device 305 (and/or the aforementioned cell deformation structures 50, 150 and/or 250, and/or microfluidic devices 5, 105 and/or 205) out of a silicon substrate, rather than out of a
- microfluidic device 305 (and/or the
- microfluidic devices 5, 105 and/or 205) are preferably formed out of silicon rather than polydimethylsiloxane (PDMS) .
- PDMS polydimethylsiloxane
- Silicon allows the fabrication resolution of the device to be increased to nanoscale levels, which is helpful for achieving the desired cell constriction using cell deformation structures 350, while at the same time providing a more rigid and less deformable surface.
- microfluidic device 305 is designed using AutoCAD (Autodesk), and then microfabrication is performed using a 500-um thickness silicon wafer as the
- a layer of silicon oxide (SiC>2) is then deposited on the wafer by wet thermal oxidation (1050 °C) .
- flow channels 342 are patterned on the S1O 2 film by standard
- the channel pattern is transferred into the S1O 2 layer by reactive ion etch (RIE) in CF 4 plasma (Plasmatherm BatchTop, 15 seem CF 4 , 100 mTorr, 175W RF) .
- RIE reactive ion etch
- CF 4 plasma Pullasmatherm BatchTop, 15 seem CF 4 , 100 mTorr, 175W RF
- Etcher Pulsma-Therm Versaline ICP.
- the etching depth can be monitored using a Dektak 150 Optical Profilometer .
- the silicon substrate can then be etched by a metal-assisted chemical method in 10% HF, 122 mM H 2 O 2 to form deformation structures 350.
- microfluidic device 305 and/or the aforementioned microfluidic devices 5, 105 and/or 205) instead of polydimethylsiloxane (PDMS) provides at least two significant advantages.
- the Young's modulus of silicon is approximately 106 times higher than that of polydimethylsiloxane (PDMS), which provides a larger interaction pressure when the cell is passing through gaps 355 formed between deformation structures 350 and side walls 343 of flow channels 342.
- PDMS polydimethylsiloxane
- the fabrication resolution of a given cell deformation structure 350 can be improved down to nanoscale levels, which PDMS cannot achieve. It should also be appreciated that, if desired, cell deformation structures 350 may be replaced by (or supplemented by) other deformation structures having geometries different from the inverted funnel
- Figs. 43-47 configured to optimize the membrane porosity (the number and/or size of membrane openings) of a specific cell type while maintaining cell membrane integrity and cell
- such other deformation structures may be configured to enhance cell porosity by capitalizing on the various factors which affect cell porosity, e.g., the
- FIG. 48 and 49 there is shown an alternative cell deformation structure 350A which generally comprise a curved "hill" (or “dune") shape.
- cell deformation structures 350A are disposed on side walls
- a gap 355 e.g., a 2 pm gap
- microfluidic device which is configured to (i) mechanically deform the cell membrane of a cell so as to facilitate delivery of material into a cell, e.g., for delivery of siRNA into a cell for gene silencing, and (ii) allow for on-chip cell migration assay (e.g., for studying the phenotype transition of cancer cells to gain insights into invasiveness and migration at a tumor site) .
- Microfluidic device 405 utilizes the same general principles employed with microfluidic devices 5, 105, 205, 305 discussed above (i.e., mechanical constriction of the cell in order to temporarily disrupt the cell membrane so as to allow the passage of material into the cell), but microfluidic device 405 differs from the same general principles employed with microfluidic devices 5, 105, 205, 305 discussed above (i.e., mechanical constriction of the cell in order to temporarily disrupt the cell membrane so as to allow the passage of material into the cell), but microfluidic device 405 differs from the
- microfluidic devices 5, 105, 205 and 305 in several significant aspects.
- microfluidic device 405 generally comprises a base chip 410, a cover chip (not shown) disposed over base chip 410 (i.e., so as to form, in conjunction with one another, a closed chamber), and a plurality of structures which extend between base chip 410 and the cover chip, such that a fluid (e.g., a suspension of cells) can be selectively passed through a flow chamber 420 located between base chip 410 and the cover chip, as will hereinafter be discussed in further detail.
- Flow chamber 420 is divided into two sections: a cell deformation section 422 and a cell migration section 423.
- flow chamber 420 comprises one or more inlets 425A,
- Inlet 425B is in fluid communication with cell deformation section 422, which is in fluid communication with cell migration section 423, whereby to allow a fluid (e.g., a
- Inlets 420A and 420C, and outlets 430A, 430B and 430C, are in fluid
- Cell deformation section 422 preferably comprises two or more cell deformation structures 450.
- Each cell deformation structure 450 preferably comprises a
- deformation structure 450 comprises a body 452 and a plurality of angled arms 453 directed away from body 452 (Figs. 50, 51 and 53) .
- gaps 455 are 5 pm wide, however, it should be appreciated that gaps 455 may be larger or smaller depending on the cells that are to be passed through cell deformation section 422 (e.g., gap 455 may comprise a gap of between 2 pm and 10 pm) .
- structure 450 may be angled away from the longitudinal axis of body 452 of that particular cell deformation structure at various angles.
- body 452 of that particular cell deformation structure may be angled away from the longitudinal axis of body 452 of that particular cell deformation structure at various angles.
- arms 453 are angled away from the
- Cell migration section 423 preferably comprises a plurality of traps 424 (Fig. 50) disposed along the length of flow channel 420, preferably in-line with gaps 455 defined by cell deformation structures 450 of cell deformation section 422.
- Each trap 424 comprises a concave structure defined by a pair of arms 426 separated by a central gap 427.
- arms 426 can be spaced/curved so as to define a concavity 426A having an opening that is 30 pm across and a gap 427 that is 2 pm wide (see Fig.
- Cell migration section 423 also preferably comprises a plurality of migration chambers 428
- Figs. 50 and 52 are meant to be schematic in nature, in the sense that migration chambers 428 are shown generalized in Fig. 50 and microchannels 429 are shown generalized in Fig. 52. In one preferred form of the invention, migration microchannels 429 are approximately 8 pm wide and 500 pm long.
- a fluid e.g., a suspension of cells, such as MDA-MB-231 cancer cells
- inlet 425B a fluid
- squeeze past gaps 455 between adjacent cell deformation structures 450 As this occurs,
- individual cells are mechanically deformed by contact with adjacent arms 453 on either side of gaps 455, whereby to allow material (e.g., siRNA) present in the fluid to pass through the cell membrane and into the cell, whereby to alter the cell.
- material e.g., siRNA
- traps 424 may be sized to capture more or less cells, and/or traps 424 may be differently configured depending upon what cells are to be contained in the traps.
- Microfluidic device 405 (containing altered cells now trapped within traps 424) is then incubated for a desired period (e.g., 2-3 days) with fresh media being perfused into the cell (e.g., by gravity flow) to allow the cells to grow.
- a chemotaxis-inducing gradient can then be introduced into microfluidic device 405.
- a chemotaxis-inducing gradient may be introduced by passing a chemotactic agent (e.g., fetal bovine serum, FBS) into one or more of inlets 425A and 425C) , whereby to promote the migration of cells out of traps 424 and into migration microchannels 429.
- a chemotactic agent e.g., fetal bovine serum, FBS
- FBS fetal bovine serum
- characteristics of unaltered control cells, and/or altered cells may exhibit different morphology than unaltered control cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Sustainable Development (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Clinical Laboratory Science (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The CRISPR (clustered regularly interspaced short palindromic repeats) -Cas (CRISPR-associated) nuclease system represents an efficient tool for genome editing and gene function analysis. It consists of two components: single-guide RNA (sgRNA) and the enzyme Cas9. Typical sgRNA and Cas9 intracellular delivery techniques are limited by their reliance on cell type and exogenous materials as well as their toxic effects on cells (for example, electroporation). The present invention introduces and optimizes a microfluidic membrane deformation method to deliver sgRNA and Cas9 into different cell types and achieve successful genome editing. This approach uses rapid cell mechanical deformation to generate transient membrane holes to enable delivery of biomaterials in the medium. The present invention has achieved high delivery efficiency of different macromolecules into different cell types, including hard-to-transfect lymphoma cells and embryonic stem cells, while maintaining high cell viability. With the advantages of broad applicability across different cell types, particularly hard-to-transfect cells, and flexibility of application, this method can enable new avenues of biomedical research and gene targeting therapy such as mutation correction of disease genes through combination of the CRISPR-Cas9-mediated knockin system.
Description
CRISPR-CAS9 DELIVERY TO HARD-TO-TRANSFECT
CELLS VIA MEMBRANE DEFORMATION
Reference To Pending Prior Patent Applications
This patent application:
(i) claims benefit of pending prior U.S.
Provisional Patent Application Serial No. 62/243,275, filed 10/19/2015 by The Methodist Hospital and Lidong Qin for CRISPR-CAS9 DELIVERY TO HARD-TO-TRANSFECT CELLS VIA MEMBRANE DEFORMATION (Attorney's Docket No. METHODIST-28 PROV) ; and
(ii) claims benefit of pending prior U.S.
Provisional Patent Application Serial No. 62/252,337, filed 11/06/2015 by The Methodist Hospital and Lidong Qin et al . for CRISPR-CAS9 DELIVERY CHIP (BACK AND FORTH CHIP) (Attorney's Docket No. METHODIST-29 PROV) .
The two (2) above-identified patent applications are hereby incorporated herein by reference.
Field Of The Invention
This invention relates to cell transfection in general, and more particularly to CRISPR-Cas9 delivery to hard-to-transfect cells.
Background Of The Invention
The CRISPR (clustered regularly interspaced short palindromic repeats) -Cas (CRISPR-associated) nuclease system is an easy-to-use, highly specific, efficient, and multiplexable genome editing tool that has been used in various organisms, including human and mouse cell lines. See P. Mali, L. Yang, K. M. Esvelt, J. Aach, M. Guell, J. E. DiCarlo, J. E. Norville, G. M. Church, RNA guided human genome engineering via Cas9.
Science 339, 823-826 (2013); L. Cong, F. A. Ran, D. Cox, S. Lin, R. Barretto, N. Habib, P. D. Hsu, X. Wu, W. Jiang, L. A. Marraffini, F. Zhang, Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013); and P. D. Hsu, E. S. Lander, F. Zhang,
Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262-1278 (2014) . In the two- component system, a single-guide RNA (sgRNA) directs Cas9 nuclease to introduce sequence-specific targeted loss-of function mutations into the genome. See P. D.
Hsu, E. S. Lander, F. Zhang, Development and
applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262-1278 (2014); and W. Xue, S. Chen, H.
Yin, T. Tammela, T. Papagiannakopoulos, N. S. Joshi,W. Cai, G. Yang, R. Bronson, D. G. Crowley, F. Zhang, D. G. Anderson, P. A. Sharp, T. Jacks, CRISPR mediated direct mutation of cancer genes in the mouse liver. Nature 514, 380-384 (2014). Cas9 can be easily programmed to induce DNA double-strand breaks through RNA guides, which can generate insertions and
deletions (indels) and stimulate genome editing at specific target genomic loci. See T. Wang, J. J. Wei, D. M. Sabatini, E. S. Lander, Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84 (2014); and 0. Shalem, N. E. Sanjana, E. Hartenian, X. Shi, D. A. Scott, T. S. Mikkelsen, D. Heckl, B. L. Ebert, D. E. Root, J. G. Doench, F. Zhang, Genome- scale CRISPR-Cas9 knockout screening in human cells.
Science 343, 84-87 (2014) . The ability to perturb the genome in a precise and targeted manner is crucial to understanding genetic contributions to biology and disease. See P. D. Hsu, E. S. Lander, F. Zhang,
Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262-1278 (2014); and K. High, P. D. Gregory, C. Gersbach, CRISPR technology for gene therapy. Nat. Med. 20, 476-477 (2014).
Successful delivery of sgRNA and Cas9 into cells facilitates efficient genome editing. Typical
intracellular delivery techniques use liposomes or polymeric nanoparticles to induce cell membrane poration or endocytosis. See F. Heitz, M. C. Morris,
G. Divita, Twenty years of cell-penetrating peptides : From molecular mechanisms to therapeutics . Br. J.
Pharmacol. 157, 195-206 (2009); A. Verma, 0. Uzun, Y. Hu, Y. Hu, H. S. Han, N. Watson, S. Chen, D. J.
Irvine, F. Stellacci , Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles . Nat. Mater. 7, 588-595 (2008); J.
Zabner, Cationic lipids used in gene transfer . Adv. Drug Deliv. Rev. 27, 17-28 (1997); and H. Duan, S. Nie, Cell-penetrating quantum dots based on
multivalent and endosome-disrupting surface coatings. J. Am. Chem. Soc. 129, 3333-3338 (2007). Recently, cell-penetrating peptide-mediated delivery of sgRNA and Cas9 has been used for gene disruption. See S. Ramakrishna, A. B. Kwaku Dad, J. Beloor, R. Gopalappa,
S. K. Lee, H. Kim, Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. 24, 1020-1027 (2014). In these methods, delivery efficiency is often dependent on cell type and the structure of the target molecule.
Electroporation is an attractive alternative for many applications and allows highly efficient RNA-guided genome editing via delivery of purified Cas9
ribonucleoprotein . See M. B. Fox, D. C. Esveld, A. Valero, R. Luttge, H. C. Mastwijk, P. V. Bartels, A. van den Berg, R. M. Boom, Electroporation of cells in microfluidic devices: A review. Anal. Bioanal . Chem. 385, 474-485 (2006); S. Li, Electroporation gene
therapy: New developments in vivo and in vitro. Curr. Gene Ther. 4, 309-316 (2004); and S. Kim, D. Kim, S. W. Cho, J. Kim, J. S. Kim, Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins . Genome Res. 24, 1012-1019 (2014) . However, this method can cause cell damage and generate a high cell death rate. Moreover, commonly used virus ( adeno-associated virus,
retrovirus, or lentivirus ) -mediated delivery of sgRNA and Cas9 is often associated with uncontrolled
chromosomal integration, limiting its clinical
potential. See Y. C. Hu, Baculoviral vectors for gene delivery : A review. Curr. Gene Ther. 8, 54-65 (2008) ; and R. Waehler, S. J. Russell , D. T. Curiel,
Engineering targeted viral vectors for gene therapy . Nat. Rev. Genet. 8, 573-587 (2007).
Rapid mechanical deformation of cells can produce transient membrane disruptions that facilitate passive diffusion of material into the cytosol. Using
physical constriction to deform and shear cells for delivery has achieved high efficiency with low cell death rate. This method has the advantage of high- throughput delivery of almost any macromolecule into almost any cell type. See A. Sharei, J. Zoldan, A. Adamo, W. Y. Sim, N. Cho, E. Jackson, S. Mao, S.
Schneider, M. J. Han, A. Lytton-Jean, P. A. Basto, S. Jhunjhunwala, J. Lee, D. A. Heller, J. W. Kang, G. C. Hartoularos, K. S. Kim, D. G. Anderson, R. Langer, K.
F. Jensen, A vector-free microfluidic platform for intracellular delivery. Proc. Natl. Acad. Sci . U.S.A. 110, 2082-2087 (2013). Membrane deformation-based microfluidic devices have been used in the delivery of a range of materials such as carbon nanotubes, proteins, and short interfering RNAs (siRNAs) . They have been used for delivering transcription factors for cell reprogramming . See A. Sharei, J. Zoldan, A. Adamo, W. Y. Sim, N. Cho, E. Jackson, S. Mao, S.
Schneider, M. J. Han, A. Lytton-Jean, P. A. Basto, S.
Jhunjhunwala, J. Lee, D. A. Heller, J. W. Kang, G. C. Hartoularos, K. S. Kim, D. G. Anderson, R. Langer, K. F. Jensen, A vector-free microfluidic platform for intracellular delivery. Proc. Natl. Acad. Sci. U.S.A. 110, 2082-2087 (2013).
Summary Of The Invention
Microfluidic membrane deformation has the
potential to serve as a broad-based universal delivery platform and boasts the advantages of precise control over treatment conditions at the single-cell level, with macroscale throughput.
The present invention comprises the provision and use of a novel microfluidic platform which optimizes the physical constriction in a microfluidic setup, considering both delivery efficiency and cell
viability. The present invention allows successful delivery of single-stranded DNA (ssDNA), siRNAs, and
large-sized plasmids into different cell types, including adherent and non-adherent cells, hard-to- transfect lymphoma, and embryonic stem cells. Sequence analysis, together with biochemical and functional analyses, demonstrates highly efficient genome editing and successful generation of gene-knockout cell lines, using the present invention with different cell types.
It is believed that the present invention
provides the first demonstration of membrane
deformation for CRISPR/Cas9 gene editing. Thus, it is believed that the new microfluidic delivery method of the present invention will facilitate RNA-guided genome editing and gene loss-of-function analysis across different cell types, especially difficult-to- transfect cells. Achievement of high genome editing efficiency in non-adherent lymphoma cells suggests that the approach utilized with the present invention also has potential for clinical use.
In one preferred form of the present invention, there is provided a system for transfecting cells, the system comprising:
a microfluidic device comprising:
a housing having a flow passageway formed therein, the flow passageway comprising a port; and a cell deformation zone formed within the flow passageway, the cell deformation zone comprising a plurality of cell deformation structures spaced laterally across the flow passageway and serially
along the flow passageway, wherein the laterally- spaced cell deformation structures define a plurality of gaps therebetween, wherein each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap.
In another preferred form of the present
invention, there is provided a method for transfecting cells, the method comprising:
providing a system for transfecting cells, the system comprising:
a microfluidic device comprising:
a housing having a flow passageway formed therein, the flow passageway comprising a port; and
a cell deformation zone formed within the flow passageway, the cell deformation zone
comprising a plurality of cell deformation structures spaced laterally across the flow passageway and serially along the flow passageway, wherein the laterally-spaced cell deformation structures define a plurality of gaps therebetween, wherein each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap; and
introducing into the flow passageway (i) a plurality of cells to be transfected, and (ii) the
material to be transfected into the plurality of cells .
In another preferred form of the present
invention, there is provided a system for transfecting cells, the system comprising:
a microfluidic device comprising:
a housing having a flow passageway formed therein, the flow passageway comprising a port;
a cell deformation zone formed within the flow passageway, the cell deformation zone comprising a plurality of cell deformation structures defining a plurality of gaps therebetween, wherein each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap;
a plurality of cells to be transfected; and material to be transfected into the plurality of cells, wherein the material to be transfected into the plurality of cells comprises plasmids encoding sgRNA and plasmids encoding Cas9 protein.
In another preferred form of the present
invention, there is provided a method for transfecting cells, the method comprising:
providing a system for transfecting cells, the system comprising:
a microfluidic device comprising:
a housing having a flow passageway formed therein, the flow passageway comprising a port;
a cell deformation zone formed within the flow passageway, the cell deformation zone
comprising a plurality of cell deformation structures defining a plurality of gaps therebetween, wherein each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap;
a plurality of cells to be transfected; and
material to be transfected into the plurality of cells, wherein the material to be
transfected into the plurality of cells comprises plasmids encoding sgRNA and plasmids encoding Cas9 protein; and
introducing into the flow passageway a plurality of cells to be transfected, and the material to be transfected into the plurality of cells.
In another preferred form of the present
invention, there is provided a system for transfecting cells, the system comprising:
a microfluidic device comprising:
a housing having a flow passageway formed therein, the flow passageway comprising a port; and a cell deformation zone formed within the flow passageway, the cell deformation zone comprising a plurality of flow channels, wherein the plurality of flow channels each comprise a first wall and a second
wall, wherein the first wall and the second wall are spaced apart so as to define a flow path therebetween;
at least one cell deformation structure extending away from the first wall of a given flow channel into the flow path of that flow channel, the at least one cell deformation structure being spaced away from the second wall of that flow channel such that a gap is disposed between the at least one cell deformation structure and the second wall, wherein the gap is sized such that a cell passing through the gap is mechanically deformed as the cell passes through that gap.
In another preferred form of the present
invention, there is provided a method for transfecting cells, the method comprising:
providing a system for transfecting cells, the system comprising:
a microfluidic device comprising:
a housing having a flow passageway formed therein, the flow passageway comprising a port; and
a cell deformation zone formed within the flow passageway, the cell deformation zone
comprising a plurality of flow channels, wherein the plurality of flow channels each comprise a first wall and a second wall, wherein the first wall and the second wall are spaced apart so as to define a flow path therebetween;
at least one cell deformation structure extending away from the first wall of a given flow channel into the flow path of that flow channel, the at least one cell deformation structure being spaced away from the second wall of that flow channel such a gap is disposed between the at least one cell deformation structure and the second wall, wherein the gap is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap; and
introducing into the flow passageway (i) a plurality of cells to be transfected, and (ii) the material to be transfected into the plurality of cells .
In another preferred form of the present
invention, there is provided a system for transfecting cells, the system comprising:
a microfluidic device comprising:
a housing having a flow passageway formed therein, the flow passageway comprising a port;
a cell deformation zone formed within the flow passageway, the cell deformation zone comprising a plurality of cell deformation structures defining a plurality of gaps therebetween, wherein each of the cell deformation structures comprises a body and a plurality of arms extending away from the body, wherein at least two cell deformation structures are arranged parallel to one another such that a plurality
of gaps exist between the plurality of arms of the cell deformation structures, and further wherein each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap.
In another preferred form of the present
invention, there is provided a method for transfecting cells, the method comprising:
providing a system for transfecting cells, the system comprising:
a microfluidic device comprising:
a housing having a flow passageway formed therein, the flow passageway comprising a port;
a cell deformation zone formed within the flow passageway, the cell deformation zone
comprising a plurality of cell deformation structures defining a plurality of gaps therebetween, wherein each of the cell deformation structures comprises a body and a plurality of arms extending away from the body, wherein at least two cell deformation structures are arranged parallel to one another such that a plurality of gaps exist between the plurality of arms of the cell deformation structures, and further wherein each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap;
a plurality of cells to be transfected; and
material to be transfected into the plurality of cells; and
introducing into the flow passageway a plurality of cells to be transfected, and the material to be transfected into the plurality of cells.
In another preferred form of the present
invention, there is provided a system for transfecting cells, the system comprising:
a microfluidic device comprising:
a housing having a flow chamber formed therein, the flow chamber comprising at least one inlet ;
a cell deformation section formed within the flow chamber, the cell deformation section comprising a plurality of cell deformation structures defining a plurality of gaps therebetween, and wherein each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap;
a cell migration section formed within the flow chamber and fluidically connected to the cell deformation section, the cell migration section comprising a plurality of traps arrayed serially along the flow chamber and a plurality of migration
microchannels disposed perpendicular to the
longitudinal axis of the flow chamber and fluidically connected to the flow chamber.
In another preferred form of the present
invention, there is provided a method for transfecting and chemotactically separating cells, the method comprising :
providing a system for transfecting cells, the system comprising:
a microfluidic device comprising: a housing having a flow chamber formed therein, the flow chamber comprising at least one inlet ;
a cell deformation section formed within the flow chamber, the cell deformation section comprising a plurality of cell deformation structures defining a plurality of gaps therebetween, and wherein each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap;
a cell migration section formed within the flow chamber and fluidically connected to the cell deformation section, the cell migration section comprising a plurality of traps arrayed serially along the flow chamber and a plurality of migration
microchannels disposed perpendicular to the
longitudinal axis of the flow chamber and fluidically connected to the flow chamber;
a plurality of cells to be transfected; and material to be transfected into the plurality of cells; and
introducing into the flow chamber a plurality of cells to be transfected, and the material to be transfected into the plurality of cells;
flowing the plurality of cells to be transfected, and the material to be transfected into the plurality of cells, through the cell deformation section such that some of the cells are transfected;
flowing the plurality of cells to be transfected, the material to be transfected into the plurality of cells, and the transfected cells into the cell
migration section such that at least some of the cells are retained in the cell migration section;
incubating the housing for a pre-determined period of time;
introducing a chemotactic gradient into the cell migration section; and
allowing the cells retained in the cell migration section to migrate into one or more of the migration microchannels along the chemotactic gradient.
Brief Description Of The Drawings
These and other objects and features of the present invention will be more fully disclosed or rendered obvious by the following detailed description of the preferred embodiments of the invention, which is to be considered together with the accompanying drawings wherein like numbers refer to like parts, and further wherein:
Fig. 1A is a schematic view showing a novel microfluidic device formed in accordance with the present invention;
Fig. IB is a schematic view showing how plasmids encoding sgRNA and Cas9 protein can be passed into a cell using the novel microfluidic device of Fig. 1A;
Fig. 1C is a schematic view showing further aspects of the novel microfluidic device of Fig. 1A;
Fig. ID is a schematic view showing a cell stress simulation of a cell being passed through the novel microfluidic device of Fig. 1A;
Figs. 2A-2F are schematic views showing
experimental results of an experiment in which FITC- labeled ssDNA was delivered into HEK293T cells using a novel microfluidic device formed in accordance with the present invention;
Figs. 3A-3E are schematic views showing
experimental results of an experiment in which cells were transformed using EGFP via a novel microfluidic device formed in accordance with the present
invention;
Figs. 4A-4E are schematic views showing
experimental results of a gene disruption experiment in which plasmids encoding both sgRNA targeting AAVSl locus or NUAK2 and Cas9 protein were delivered into
MCF7 and HeLa cells using a novel microfluidic device formed in accordance with the present invention;
Figs. 5A-5D are schematic views showing
experimental results of an experiment in which a novel microfluidic device formed in accordance with the present invention was used for cell phenotype and gene function analysis;
Fig. 6A is a schematic view showing various cell deformation structures which may be used in a novel microfluidic device formed in accordance with the present invention;
Figs. 6B and 6C are schematic views showing experimental results of cells being passed through novel microfluidic devices formed in accordance with the present invention, wherein the various cell deformation structures of Fig. 6A have been
incorporated into the novel microfluidic devices;
Fig. 6D is a schematic view showing several novel microfluidic devices formed in accordance with the present invention being multiplexed;
Fig. 6E is a schematic view showing experimental results of an experiment in which HEK293T and SUM159 cells were passed through a novel microfluidic device formed in accordance with the present invention;
Fig. 7 is a schematic view showing stress
simulation of cell profusion through diamond-shaped cell deformation structures of a novel microfluidic device formed in accordance with the present
invention;
Fig. 8 is a schematic view showing flow velocity simulation of cell profusion through diamond-shaped cell deformation structures of a novel microfluidic device formed in accordance with the present
invention;
Figs. 9A-9C are schematic views showing
experimental results of an experiment in which
plasmids encoding GFP were passed into cells using FuGENE HD and delivery via a novel microfluidic device formed in accordance with the present invention;
Figs. 9D-9F are schematic views showing
experimental results of an experiment in which
plasmids encoding GFP with Phosphoglycerate Kinase 1 (PGK) promoter were passed into cells using FuGENE HD and delivery via a novel microfluidic device formed in accordance with the present invention;
Figs. 10A and 10B are schematic views showing flow cytometry analysis of an experiment in which EGFP stable expressing MDAMB231 and SU-DHL-1 lymphoma cells were delivered with plasmids encoding only Cas9 protein or both sgEGFP and Cas9 protein using a novel microfluidic device formed in accordance with the present invention;
Figs. 10C-11D are schematic views showing further aspects of the experiment of Figs. 10A and 10B;
Figs. 12 and 13A are schematic views showing another novel microfluidic device formed in accordance with the present invention;
Fig. 13B is a schematic view showing how plasmids encoding guide RNA and Cas9 protein can be passed into a cell using the novel microfluidic device of Figs. 12 and 13A;
Fig. 13C is a schematic view showing further aspects of the novel microfluidic device of Figs. 12 and 13A;
Fig. 13D is a schematic view showing a cell stress simulation of a cell being passed through the novel microfluidic device of Figs. 12 and 13A;
Figs. 14 and 15 are schematic views showing further aspects of the novel microfluidic device of Figs. 12 and 13A;
Fig. 16 is a schematic view showing a cell stress simulation of a cell being passed through the novel microfluidic device of Figs. 12 and 13;
Fig. 17 is a schematic view showing further aspects of the novel microfluidic device of Figs. 12 and 13;
Fig. 18 is a schematic view showing various cell deformation structures which may be used with the novel microfluidic device of Figs. 12 and 13A, and aspects thereof;
Figs. 19-22 are schematic views showing how a cell slurry may be passed back and forth through the novel microfluidic device of Figs. 12 and 13A;
Figs. 23-26 are schematic views showing further aspects of the novel microfluidic device of Figs. 12 and 13A;
Figs. 27 and 28 are schematic views showing another novel microfluidic device formed in accordance with the present invention;
Figs. 29A-30C are schematic views showing
experimental results of an experiment in which GFP was passed into cells using FuGENE HD and delivery via a novel microfluidic device formed in accordance with the present invention;
Fig. 31A is a schematic view showing another novel microfluidic device formed in accordance with the present invention;
Figs. 31B-31D are schematic views showing further aspects of the cell deformation structures of the novel microfluidic device of Fig. 31A;
Figs. 32A and 32B are schematic views showing the experimental results of an experiment in which 70-kDa dextran molecules and siRNA were delivered into cells using the novel microfluidic device of Fig. 31A;
Figs. 33A and 33B are schematic views showing experimental results of an experiment in which Cas9 or Cas9/tracrRNA/crRNA complex was delivered to SK-BR-3 cells using the novel microfluidic device of Fig. 31A;
Figs. 33C-35C are schematic views showing
experimental results of experiments performed on cells using the novel microfluidic device of Fig. 31A;
Fig. 36 is a schematic view showing flow velocity simulation of cell deformation of a cell passing through curved tunnel deformation structures of the novel microfluidic device of Fig. 31A;
Fig. 37 is a schematic view showing experimental results of an experiment conducted to study cell recovery rates after delivery of a target molecule using the novel microfluidic device of Fig. 31A;
Figs. 38-42 are schematic views showing
experimental results of experiments performed on cells using the novel microfluidic device of Fig. 31A;
Figs. 43-47 are schematic views showing another microfluidic device formed in accordance with the present invention;
Figs. 48 and 49 are schematic views showing another cell deformation structure which may be utilized with the present invention; and
Figs. 50-55 are schematic views showing another microfluidic device formed in accordance with the present invention.
Detailed Description Of The Preferred Embodiments
1 Results
1.1 Delivery Principle And Chip Design
When a cell passes through a constriction smaller than the cell diameter, it undergoes rapid mechanical
deformation, causing transient membrane disruption or holes. The shear and compressive forces imposed on the cell during passage through the constriction determine the degree of disruption and the size and frequency of the holes. Macromolecules small enough to pass through the holes can diffuse into the cytosol from the surrounding medium and may remain and
function in the cell after the membrane recovers from the deformation (Figs. 1A and IB) . To apply this principle, the microfluidic devices of the present invention comprise a series of constrictions of different dimensions formed by structures of different shapes (Fig . 6A) .
In a preferred form of the present invention, and looking now at Figs. 1A-1D, there is provided a novel microfluidic device 5. Microfluidic device 5
generally comprises a base chip 10 and a cover chip 15 disposed over base chip 10. A plurality of structures extend between base chip 10 and cover chip 15, with cover chip 15 being spaced from base chip 10 such that a fluid (e.g., a suspension of cells) can be
selectively passed through a flow chamber 20 located between base chip 10 and cover chip 15, as will hereinafter be discussed in further detail.
More particularly, and still looking at Figs. 1A-
1D, flow chamber 20 comprises an inlet 25 located at one end of flow chamber 20 and an outlet 30 located at the opposite end of flow chamber 20. A cell scatter
zone 35 is located proximate to inlet 25 and a cell deformation zone 40 is located downstream from cell scatter zone 35, proximate to outlet 30.
Cell scatter zone 35 comprises a plurality of cell scatter structures 45 which extend between base chip 10 and cover chip 15. Cell scatter structures 45 act to disperse and separate cells flowing through flow chamber 20, as will hereinafter be discussed. In one preferred form of the present invention, cell scatter structures 45 comprise a generally round cross-section.
Cell deformation zone 40 comprises a plurality of cell deformation structures 50 which extend between base chip 10 and cover chip 15. Cell deformation structures 50 are spaced such that adjacent cell deformation structures 50 define a gap 55
therebetween. Gap 55 is sized such that a cell which is flowed through gap 55 is engaged by two cell deformation structures 50, whereby to mechanically constrict the cell between the cell deformation structures and momentarily mechanically deform the cell membrane, whereby to allow material (e.g., Cas9, sgRNA, etc.) to enter the cell, as will hereinafter be discussed. In one preferred form of the present invention, cell deformation structures 50 comprise a generally diamond-shaped cross-section.
In one form of the present invention,
microfluidic device 5 is fabricated with standard
polydimethylsiloxane (PDMS) microfluidics technology. Each microfluidic device 5 preferably comprises 14 identical cell-scattering zones 35 and cell
deformation zones 40, and each cell deformation zone 40 preferably contains 10 arrays of cell deformation structures 50 forming microconstrictions at gaps 55 (Fig. 1C) . Cell scatter zone 35 is designed to disperse or "scatter" the cell suspension. Cell deformation zone 40 is where cells pass through microconstrictions (i.e., gaps 55), becoming deformed and generating transient membrane holes that ensure delivery of the macromolecule ( s ) of interest.
Interconnected channels within cell scatter zones 35 and cell deformation zones 40 enable high throughput of treated cells by preventing clogging. To optimize the microconstriction design, it is possible to provide constrictions using cell deformation
structures 50 of several different shapes, including circles, ellipses, and diamonds (Fig. 6A) . In an experimental test of the present invention, suspended cells were passed through flow chamber 20 of
microfluidic device 5 by flowing the cell suspension through a Tygon tube connected to inlet 25, and fluid flow was controlled by a syringe pump (not shown) . To optimize the design, a series of test deliveries of fluorescein isothiocyanate (FITC) -labeled ssDNA into human embryonic kidney 293T (HEK293T) cells were performed. The smallest constriction width (i.e., the
smallest gap 55 between adjacent cell deformation structures 50) of the three experimental designs
(circle, ellipse and diamond), 4 pm, was chosen for further experiments. Of the three experimental designs (circle, ellipse and diamond), the cell deformation structures 50 having a "diamond pattern" (i.e., a diamond-shaped cross-section) showed nearly identical delivery efficiency at a range of flowrates from 50 to 250 μΐ/min, with much higher cell viability than cell deformation structures 50 exhibiting circle or ellipse patterns (Figs. 6B and 6C) , and therefore the "diamond pattern" was chosen for cell deformation structures 50 to be used for further experiments. To maximize the functional area of cell deformation structures 50, the length of the diamond edge was minimized to 10 pm (Fig. 1C) . A "parallel"
microfluidic device design (Fig. 6D) was generated by arranging multiple microfluidic devices 5 side-by-side so as to demonstrate that delivery can be multiplexed. The cell recovery rate after delivery for both HEK293T and SUM159 cell lines was close to 100% (Fig. 6E) . In one form of the invention, cells are passed through microconstrictions (i.e., gaps 55) formed by diamond- patterned cell deformation structures 50 at a flow rate of 30 μΐ/min. Cell stress simulation (Fig. ID and Fig. 7) and flow velocity simulation (Fig. 8) were applied to the "diamond pattern" design at the time point when a cell began to penetrate the
microconstriction (i.e., when the cell entered gap 55 between adjacent cell deformation structures 50) . The novel microfluidic device 5 of the present invention can be used to successfully deliver plasmids encoding different sgRNAs and Cas9 into different types of cells and achieve precise genome editing and perform specific gene loss-of-function analysis, as depicted in Fig. IB.
1.2 Optimization Of The Delivery Chip
Specifications
To optimize the delivery performance of the novel microfluidic device 5, it is useful to take into consideration constriction dimensions, fluid flow rates, and duration of cell passage through the chip as three key parameters. In the "diamond design", where cell deformation structures 50 comprise
generally diamond-shaped cross-sections, the
constriction depth was 15 pm, and the width of gap 55 varied from 4 to 5 pm (Fig. 1C) . In pursuit of high delivery efficiency coupled with high cell viability, a series of testing deliveries of FITC-labeled ssDNA into HEK293T cells were performed (Fig. 2A) .
Experimental data showed that delivery efficiency increased with increasing flow rate across design patterns (Fig. 2B) . The 4-pm constriction width for gap 55 presented higher delivery efficiency than the 5-pm width for gap 55 at all flow rates, with minimal
effect on cell viability. Increasing the number of operational cycles with the same chip allowed multiple cell passaging times, which would also enhance the delivery efficiency; however, the operation clearly decreased cell viability (Figs. 2B and 2C) . The data for the 0 μΐ/min flowrate represents a control whereby the cells were treated exactly as the other samples but were not applied with the membrane deformation, thus ruling out the possibility that cell FITC
positivity was the result of any endocytotic or surface binding events.
1.3 Broad Applicability
To investigate the adaptability of this
technique, siRNA delivery for gene knockdown was tested. Considering both delivery efficiency and cell viability, a microconstriction (i.e., a gap 55) having a width of 4 pm, a fluid flow rate of 250 μΐ/min through flow chamber 20, and single passage of the cells through microfluidic device 5 was chosen for all subsequent experiments. When three siRNAs specific for Aktl were delivered into PC-3 cells, all of the oligos achieved >70% knockdown efficiency in 48 hours after delivery (Fig. 2D) . Moreover, depletion of Aktl by all three siRNAs suppressed cell growth, which is consistent with previous research (Fig. 2E),
indicating that the novel method and apparatus of the present invention is reliable for cell phenotype
analysis and gene function study. See T. Sasaki, K. Nakashiro, H. Tanaka, K. Azuma, H. Goda, S. Hara, J. Onodera, I. Fujimoto, N. Tanji, M. Yokoyama, H.
Hamakawa, Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo. Biochem. Biophys . Res. Commun . 399, 79-83 (2010).
To further assess the delivery ability of
microfluidic device 5 across different cell types, plasmids encoding green fluorescent protein (GFP) were used to measure the delivery efficiency. Plasmids encoding GFP were successfully delivered with high efficiency into HEK293T cells, human luminal-like MCF7 and basal-like SUM159 breast cancer cells, human SU- DHL-1 anaplastic large cell lymphoma cells, and mouse
AB2.2 embryonic stem cells (Fig. 2F), all with minimal cell death. Using the method and apparatus of the present invention, nearly the same percentage of GFP- expressing cells were achieved as is typically
obtained with traditional FuGENE HD transfection (Fig.
2F and Figs. 9A-9E) . The method and apparatus of the present invention achieved even higher efficiency than FuGENE HD transfection in human anaplastic large cell lymphoma cells and mouse embryonic stem cells without inducing stem cell differentiation (Fig. 2F and Fig.
9F), suggesting potential application in difficult-to- transfect cells. It should be appreciated that microfluidic device 5 may be optimized for different
cell types, so that further improvement can be
achieved in delivery efficiency when microfluidic device 5 is modified for use with different cell types, with the goal of establishing cell-specific delivery protocols. Thus, the various parameters of microfluidic device 5 (e.g., the relative spacing, shape and configuration of cell deformation structures 50 and/or cell scatter structures 45, the width of gap 55, etc.) may be modified to optimize performance with specific cell types.
1.4 EGFP Knockout Via Chip
Cells stably expressing enhanced GFP (EGFP) were used in an experiment in order to illustrate the potential application of the novel microfluidic device
5 of the present invention in CRISPR-Cas9-mediated genome editing. EGFP was introduced into cells with lentivirus, and the EGFP encoding sequences were integrated into chromosomal DNA. Plasmids encoding Cas9 only or sgRNAs targeting EGFP (sgEGFP-1 and sgEGFP-2) and Cas9 were delivered into adherent MDA- MB-231 cells and non-adherent SU-DHL-1 lymphoma cells. To enhance delivery efficiency, cells were passed through the same microfluidic device 5 three times. After delivery, cells were allowed to recover in culture for 7 days. Bright-field and fluorescence microscopic (Fig. 3A) and flow cytometric analyses (Fig. 3B and Fig. 10A) showed that plasmid delivery
was efficient and genome editing was successful in MDA-MB-231 cells, achieving >90% EGFP knockout
efficiency with both sgRNAs targeting different EGFP coding sequences. In SU-DHL-1 lymphoma cells, bright- field and fluorescence microscopic analyses (Fig. 3C) and flow cytometric analyses (Fig. 3D and Fig. 10B) showed >70% EGFP knockout efficiency, which was satisfactory for this difficult-to-transfect lymphoma cell line and could not be achieved by current
transfection methods. As expected, EGFP expression was not affected in the negative control cells, which were delivered with plasmids encoding Cas9 only.
To analyze the indels at the EGFP locus generated by CRISPR-Cas9-mediated genome editing, the specific sgEGFP-1 target regions were amplified by polymerase chain reaction (PCR) and TA cloning of the products was conducted in SU-DHL-1 lymphoma cells (Fig. IOC) . The results of sequence analysis showed that delivery of plasmids encoding sgRNA targeting EGFP and Cas9 into the cells via microfluidic device 5 caused different types of mutations in the EGFP locus (Fig. 3E) . These data indicate successful delivery of plasmids encoding sgRNAs and Cas9 into different human cell lines using microfluidic device 5 and the
achievement of highly efficient genome editing using microfluidic device 5.
1.5 Gene Disruption Platform
To determine whether the novel method and
apparatus of the present invention could be used for gene disruption and function analysis, further
delivery of plasmids encoding Cas9 and sgRNAs was carried out, targeting different genes in different types of cell lines. Plasmids encoding sgRNA
targeting the endogenous AAVS1 locus and Cas9 were delivered into MCF7 cells. The cells were allowed to recover in culture for 7 days, followed by PCR
amplification of the specific sgRNA target region.
The results of TA cloning and sequence analysis showed that the delivery of plasmids encoding Cas9 and sgRNA targeting AAVS1 resulted in mutations, including indels, at the specific genomic loci (Fig. 4A) .
Surveyor mutation detection assay revealed substantial cleavage at the AAVS1 locus, with indels occurring at a frequency of about 18 to 46% when delivery was optimized by passage of the cells through microfluidic device 5 three times (Fig. 4B) .
An sgRNA targeting the first exon of the NUAK2 gene was designed and cloned into a vector for
coexpression with sgRNA and Cas9 (Fig. 4C) . Plasmids encoding Cas9 and sgRNA targeting NUAK2 were delivered into HeLa cells via the membrane deformation method provided by microfluidic device 5, and the cells were allowed to recover in culture for 7 days. PCR
amplification of the sgRNA target region followed by TA cloning and sequence analysis showed deletion
mutations at the specific genomic loci (Fig. 4D) .
Mutation detection assay revealed substantial cleavage at the NUAK2 gene locus, with indels occurring at a frequency of about 30% (Fig. 4E) . The indel mutation frequencies could be optimized in a few ways such as by passing cells multiple times through the
microfluidic device 5, increasing the concentration of the plasmids, and/or by using a selective drug to kill the nontransfected cells.
In another experiment, gene function and cell phenotyping via microfluidic device 5 was explored. Plasmids encoding Cas9 and sgRNA targeting phosphatase and tensin homolog (Pten) (Fig. 11A) were delivered into MCF7 cells using microfluidic device 5, followed by culture for 48 hours and puromycin selection. More than 80% of the cells survived the selection process, indicating the high delivery efficiency of
microfluidic device 5. Cells were allowed to recover for 7 days and then analyzed by Western blotting. The results of Western blotting analysis showed that endogenous Pten expression was abolished compared with expression in control cells transfected only with plasmid encoding Cas9. Moreover, the level of Akt phosphorylation increased with Pten depletion, consistent with activation of Akt by loss of Pten
(Fig. 5A) . Cells were immunostained to further confirm successful knockout of Pten and Akt activation (Fig. 11B) . Cell proliferation was also increased in
MCF7 cells after Pten knockout (Fig. 5B) , which is consistent with a previous study. See J. Zhang, P. Zhang, Y. Wei, H. L. Piao, W. Wang, S. Maddika, M. Wang, D. Chen, Y. Sun, M. C. Hung, J. Chen, L. Ma, Deubiquitylation and stabilization of PTEN by USP13.
Nat. Cell Biol. 15, 1486-1494 (2013).
Tumor suppressor p53 binding protein 1 (53BP1) is required for DNA damage response and tumor
suppression. See S. Panier, S. J. Boulton, Double- strand break repair: 53BP1 comes into focus. Nat. Rev.
Mol. Cell Biol. 15, 7-18 (2014); J. R. Chapman, P. Barral, J. B. Vannier, V. Borel, M. Steger, A. Tomas- Loba, A. A. Sartori , I. R. Adams, F. D. Batista, S. J. Boulton, RIF1 is essential for 53BPl-dependent
nonhomologous end joining and suppression of DNA double-strand break resection. Mol. Cell 49, 858-871 (2013); and I. Rappold, K. Iwabuchi, T. Date, J. Chen, Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways . J. Cell Biol. 153, 613-620 (2001). In another experiement, an sgRNA targeting a 53BP1 gene locus was designed and used to deliver plasmids encoding both sg53BPl and Cas9 via microfluidic device 5 into HeLa cells (Fig. 11C) . Cells were cultured for 48 hours and then selected with puromycin. Similar to Pten knockout, more than 80% of 53BP1 knockout cells survived the selection process. Western blotting analysis showed the clear absence of 53BP1 expression compared with
control cells (Fig. 11D) . Camptothecin (CPT) causes DNA strand breaks mediated by transcription and induces clear 53BP1 foci in the nuclei. Here, it was shown that CPT treatment resulted in clear 53BP1 foci formation in the nuclei of control cells, but not in the cells treated with plasmids encoding both sg53BPl and Cas9 (Fig. 5C) . Consistent with this, cell survival was also greatly decreased in the cells delivered with plasmids encoding both sg53BPl and Cas9 after CPT treatment (Fig. 5D) . Together, these data show that delivery of Cas9 into HeLa cells via
microfluidic device 5 is a rapid, efficient, and high- throughput method for CRISPR-Cas9-mediated genome editing and gene knockout analysis and may provide a multiplexable and integrated platform for gene
phenotype and functional analysis.
2 Discussion
The present invention uses the mechanical
deformability of cells to generate transient holes in the cell membrane, permitting diffusion of
biomaterials in the extracellular milieu into the cytoplasm. High delivery efficiency and high cell viability was achieved with delivery of siRNAs and plasmids using microfluidic device 5. On the basis of the delivery principle, the novel method and apparatus of the present invention also have the potential to deliver other materials into the cell, such as
proteins and nanoparticles . Moreover, the novel method and apparatus of the present invention can be applied across different types of cells, including hard-to-transfect cells, such as immune cells and stem cells, to address clinical needs. By analyzing the specific deformations experienced by different types of cells passing through a microconstriction, device parameters can be optimized to achieve excellent performance with a wide range of cell types and applications.
The mechanical deformability-based principle used with the novel apparatus of the present invention provides a new solution for delivery and has
advantages over some existing methods. It is believed that the present invention provides the first
application of this microfluidic deformation method to the delivery of the CRISPR-Cas9 system to achieve genome editing and gene disruption. Similar to microinjection, the novel method and apparatus of the present invention do not rely on cell type or the structure of the target molecule; however, the present invention is easier to use with higher throughput than microinjection. See Y. Zhang, L. C. Yu,
Microinjection as a tool of mechanical delivery . Curr . Opin. Biotechnol . 19, 506-510 (2008); and D. Luo, W.
M. Saltzman, Synthetic DNA delivery systems. Nat.
Biotechnol. 18, 33-37 (2000). Electroporation has been successfully applied to CRISPR-Cas9 delivery and
allows highly efficient RNA-guided genome editing. However, unlike the microfluidic method of delivery utilized in the present invention, electroporation damages cells and often affects cell viability. The high delivery efficiency and associated high cell viability achieved using the novel method and
apparatus of the present invention facilitates efficient genome editing and precise gene functional analysis. To increase genome editing activity, the cells may be passed multiple times through
microfluidic device 5, the concentration of the plasmids may be increased, and/or a selective drug may be used to kill the nontransfected cells. Using stable Cas9-expressing cells for sgRNA delivery or Cas9 protein/ sgRNA co-complexes may also be helpful to increase the indel frequencies. In view of the successful demonstration of deformation-based
CRISPR/Cas9 gene editing achievable with the present invention, it is expected that the present invention cmay be utilized with many other cells and model systems .
The use of microfluidics-based platforms such as the present invention as a basic research tool has the advantage that it is capable of integration and incorporation into a larger system including multiple posttreatment modules. This enables potential integration of our CRISPR-Cas9 system delivery and gene loss-of-function or mutation correlation
analysis. For example, microfluidic device 5 could be integrated with a single-cell protrusion microfluidic chip for screening genes potentially involved in cell protrusion mechanics. See K. Zhang, C. K. Chou, X. Xia, M. C. Hung, L. Qin, Block-Cell-Printing for live single-cell printing. Proc. Natl. Acad. Sci . U.S.A. Ill, 2948-2953 (2014) . Use of the novel methods and apparatus of the present invention would generate large quantities of CRISPR-Cas9-mediated knockout or knockin cells for high throughput cell phenotypic screening .
CRISPR-Cas9-mediated delivery for gene therapy has been reported recently for correction of some mutations associated with disease. See K. High, P. D. Gregory, C. Gersbach, CRISPR technology for gene therapy. Nat. Med. 20, 476-477 (2014); Y. Wu, H. Zhou, X. Fan, Y. Zhang, M. Zhang, Y. Wang, Z. Xie, M. Bai, Q. Yin, D. Liang, W. Tang, J. Liao, C. Zhou, W. Liu, P. Zhu, H. Guo, H. Pan, C. Wu, H. Shi, L. Wu, F. Tang, J. Li, Correction of a genetic disease by CRISPR-Cas9- mediated gene editing in mouse spermatogonia! stem cells. Cell Res. 25, 67-79 (2015); H. Yin, W. Xue, S. Chen, R. L. Bogorad, E. Benedetti, M. Grompe, V.
Koteliansky, P. A. Sharp, T. Jacks, D. G. Anderson, Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype . Nat. Biotechnol. 32, 551-553 (2014); Y. Wu, D. Liang, Y. Wang, M. Bai, W. Tang, S. Bao, Z. Yan, D. Li, J. Li, Correction of a
genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell 13, 659-662 (2013); and G. Schwank, B. K. Koo, V. Sasselli , J. F. Dekkers, I. Heo, T. Demircan, N. Sasaki, S. Boymans, E. Cuppen, C. K. van der Ent, E. E. Nieuwenhuis, J. M. Beekman, H. Clevers,
Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13, 653-658 (2013). The present invention enables novel approaches to this type of gene therapy. With the novel methods and apparatus of the present invention, high delivery efficiency has been achieved compared with traditional liposome-mediated delivery in SUDHL-1 lymphoma cells, and successful application in anaplastic large cell lymphoma cells provides the possibility of delivery in primary patient cells. For example, a patient's target cells could be isolated from blood or other tissue, treated with the novel method and apparatus of the present invention to deliver the CRISPR-Cas9 knockin system with wild-type template to correct the disease gene mutation, and then reintroduced into the patient. The enhanced delivery efficiency provided by the present invention would increase the likelihood of correcting disease mutation genes by gene targeting therapy.
3 Materials And Methods
3.1 Materials And Reagents
SPR 220-7 photoresist was purchased from Rohm and Haas Electronic Materials. PDMS (GE 615 RTV) was purchased from Fisher Scientific. Tygon tubing was purchased from Saint-Gobain . Flat steel pins were purchased from New England Small Tube. Fetal bovine serum (FBS), trypsin, and penicillin-streptomycin were purchased from Fisher Scientific. Dulbecco's modified Eagle's medium (DMEM) , Ham's F-12 medium, RPMI 1640 and F-12K medium, insulin, hydrocortisone, and
phosphate-buffered saline (PBS) were purchased from
Life Technologies. FITC-labeled ssDNA DNA was
purchased from Integrated DNA Technologies. SiRNAs targeting Aktl (siAktl-1 SAS I_Hs 01_00105952 , siAktl-2 SASI_Hs01_00105953, and siAktl-3 SAS I_Hs 01_00105954 ) were used previously and purchased from Sigma-Aldrich.
See X. Han, D. Liu, Y. Zhang, Y. Li, W. Lu, J. Chen, Z. Songyang, Akt regulates TPP1 homodimeri zation and telomere protection . Aging Cell 12, 1091-1099 (2013). Plasmids encoding sgRNA and Cas9 were purchased from Addgene, and specific sgRNA target sequences were cloned into the CRISPR v2 vector (Addgene plasmid #52961) . The 20-bp target sequences of sgRNAs
targeting EGFP, AAVS1, and Pten were used previously. See W. Xue, S. Chen, H. Yin, T. Tammela, T.
Papagiannakopoulos, N. S. Joshi,W. Cai, G. Yang, R.
Bronson, D. G. Crowley, F. Zhang, D. G. Anderson, P. A. Sharp, T. Jacks, CRISPR mediated direct mutation of cancer genes in the mouse liver. Nature 514, 380-384
(2014); T. Wang, J. J. Wei, D. M. Sabatini, E. S.
Lander, Genetic screens in human cells using the
CRISPR-Cas9 system. Science 343, 80-84 (2014); and 0. Shalem, N. E. Sanjana, E. Hartenian, X. Shi, D. A. Scott, T. S. Mikkelsen, D. Heckl, B. L. Ebert, D. E. Root, J. G. Doench, F. Zhang, Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87
(2014). The 20-bp target sequences of the indicated sgRNAs were as follows: sgEGFP-1,
GGGCGAGGAGCTGTTCACCG; sgEGFP-2, GAGCTGGACGGCGACGTAAA; sgAAVSl, GGGGCCACTAGGGACAGGAT; sgNUAK2 ,
TTGATCAGCCCTTCCGCCAG; sgPten, AGATCGTTAGCAGAAACAAA; sg53BPl, CATAATTTATCATCCACGTC . The primers used for PCR amplification of sgRNA target regions were as follows: EGFP-FP, ATGGTGAGCAAGGGCGAGGA; EGFP-RP,
TTACTTGTACAGCTCGTCCA; AAVS1-FP, CCCCGTTCTCCTGTGGATTC ; AAVS1-RP, ATCCTCTCTGGCTCCATCGT; NUAK2-FP,
GCTTTACTGCGCGCTCTGGTACTGC; NUAK2-RP,
CAGGCGCCCCGAGCTCTCCC .
3.2 Chip Design And Fabrication
The microchip pattern of microfluidic device 5 was designed with AutoCAD (Autodesk) . Each
microfluidic device 5 consists of 14 identical cell- scatter zones 35 and cell deformation zones 40, and each cell deformation zone contains 10 arrays of constrictions (i.e., cell deformation structures 50) . The constriction depth (i.e., the distance between
base chip 10 and cover chip 15) is 15 pm, and the width of gaps 55 between adjacent cell deformation structures 50 varies from 4 to 5 pm. The parallel chip design was generated by arranging multiple microfluidic devices 5 side-by-side. Microfluidic device 5 was fabricated using standard
photolithography and soft lithography techniques. The negative photoresist SU8-3025 (MicroChem) was used to fabricate patterns on a silicon wafer. The silicon wafer was then silanized using trimethylchlorosilane (Thermo Scientific) for 30 min to facilitate PDMS mold release. PDMS prepolymer (10A:1B, Sylgard 184 silicone elastomer kit, Dow Corning) was poured onto the silicon wafer and cured at 80°C for 1 hour. Holes were then punched in the PDMS for the inlets 25 and outlets 30, and oxygen plasma treatment was used to chemically bond the PDMS mold (the base chip) to a glass slide (the cover chip) . 3.3 Finite Element Method
The flow velocity distribution, cell trajectory, and stress on the cell were simulated using the finite element method. To perform the temporal simulation, the fluidic dynamics equation (incompressible Navier- Stokes equations) and solid mechanics equation
(Newton's Second Law of motion) were coupled and implemented by fluid-solid interactions. This
combined the spatial frame interface for fluid flow
and the material frame for the cell. The mesh
geometry was continuously moved and deformed by applying the arbitrary Lagrangian-Eulerian method. The dimensions of model geometries and mechanical properties were identical to the actual experiment. The stress on the cell was computed as the von Mises stress, which is a scalar value determined from the stress tensor of a particle under the pressure in fluid flow.
3.4 Cell Culture
HEK293T, MCF7 , MDA-MB-231, and HeLa cells were grown in DMEM supplemented with 10% FBS and 1%
penicillin-streptomycin in a humidified atmosphere of 5%C02/95% air at 37°C. PC-3 cells were grown in F-12K medium supplemented with 10% FBS and 1% penicillin- streptomycin. SUM159 cells were grown in Ham's F-12 medium supplemented with 5% FBS, 1% penicillin- streptomycin, insulin (5 pg/ml), and hydrocortisone (1 pg/ml) . Human SU-DHL-1 anaplastic large cell lymphoma cells were cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin-streptomycin. Mouse AB2.2 embryonic stem cells were maintained on a 0.1% gelatin ( Sigma-Aldrich) -coated tissue culture dish in high- glucose DMEM, supplemented with 15% FBS, 55 μΜ β- mercaptoethanol (Life Technologies), and 0.01% mouse leukemia inhibitory factor (Millipore) under feeder- free conditions.
3.5 Delivery Procedure And Puromycin
Selection
The channels in microfluidic device 5 were wetted with PBS and blocked with 1% bovine serum albumin in PBS for 10 min. Cells were first suspended in the desired volume of Opti-MEM medium (Life Technologies) and then mixed with the desired amount of delivery material (ssDNA, siRNA, or plasmid) and loaded into plastic Tygon tubing with a 5-ml syringe. The tubing was then connected to inlet 25 of microfluidic device 5 by a flat steel pin. During the flow experiments, a syringe pump controlled the fluid flow through flow chamber 20 of microfluidic device 5. Treated cells were incubated in a 37°C incubator for 20 min to recover before further treatment.
Plasmids encoding both Cas9 and sgRNA targeting Pten or 53BP1 were delivered into MCF7 or HeLa cells, respectively, via microfluidic device 5. After 48 hours of culture, the cells were grown in DMEM
supplemented with 10% FBS, 1% penicillin-streptomycin, and puromycin (2 pg/ml; Sigma) for 2 to 3 days to kill the undelivered cells.
3.6 Immunostaining, Western Blotting, And Flow Cytometry
Cells grown overnight on coverslips were fixed paraformaldehyde and then permeabilized with 0.5
Triton X-100 plus 300 mM sucrose. Cells were then immunostained and visualized under an Olympus FV1000 confocal microscope. The primary antibodies used were anti-53BPl (NB100-304, Novus Biologicals ) , anti-Oct4 (abl8976, Abeam), anti-Pten (abl30224, Abeam), and anti-phospho-Akt (Ser473) (ab81283, Abeam) . The secondary antibodies used were Alexa Fluor 488- conjugated goat anti-mouse (A-11001, Life
Technologies) and Texas red-conjugated goat anti- rabbit (T-2767, Life Technologies) .
For Western blotting after siRNA-mediated
knockdown or sgRNACas9-mediated knockout, cells were allowed to recover in culture for 2 or 7 days, respectively. The primary antibodies used were anti- Aktl (ab32505, Abeam), anti-53BPl (ab21083, Abeam), and anti-actin (A3853, Sigma-Aldrich) . For flow cytometric analysis after sgEGFP-mediated knockout, cells were allowed to recover in culture for 7 days followed by analysis of EGFP fluorescence with a BD LSRFortessa cell analyzer.
3.7 Mutation Detection Assay, TA Cloning, And Sequencing
Genomic DNA was extracted using the PureLink Genomic DNA Mini Kit (K1820-00, Life Technologies) according to the manufacturer's instructions. PCR amplicons of nuclease target sites were generated and analyzed for the presence of mismatch mutations using
the Transgenomic Surveyor Mutation Detection Kit
(Integrated DNA Technologies) according to the
manufacturer's instructions. Briefly, PCR amplicons of sgRNA target regions were denatured by heating for 10 min at 95°C, annealed to form heteroduplex DNA using a thermocycler from 95°C to 25°C at -0.3°C/s, digested with Surveyor Nuclease S for 2 hours at 42°C, and separated by 1% agarose gel electrophoresis. For sequence analysis, PCR products corresponding to genomic modifications were cloned into pCR4-TOPO vector using the TOPO TA Cloning Kit (Life
Technologies) . Cloned products were sequenced using the M13 primer.
3.8 Cell Proliferation Assay, CPT Treatment, And Sensitivity Assay
After chip-mediated delivery using microfluidic device 5 and recovery in culture for siRNA knockdown or sgRNA-Cas9-mediated knockout, cells (5 χ 104) were seeded in 60-mm dishes in complete medium and cultured for 7 days. Cells were harvested by trypsinization daily and counted in a Countess II FL Automated Cell Counter (Life Technologies) .
To assess CPT sensitivity, cells were treated with 1 μΜ CPT for 2 hours and immunostained with anti- 53BP1 or treated with 10, 20, 30, or 40 nM CPT for sensitivity assay. CPT sensitivity was assessed by colony survival assay. Briefly, CPT-treated cells
(500 to 1000) were plated in 60-mm dishes in complete medium and incubated for 2 to 3 weeks to form clones. Clones were stained with Coomassie blue, and survival rate was calculated.
4 Back and Forth Chip
CRISPR-Cas9 technology is a powerful tool for genome editing in both research and therapeutics such as induced pluripotent stem cell applications and cancer immune therapy. The ability to deliver sgRNA and Cas9 in a variety of cell types, particularly hard-to-transfect cells with both high delivery efficiency and high cell viability, is critical in therapeutic and research applications.
However, passing the cell slurry through
microfluidic device 5 a single time may not result in a sufficient number of cells being transfected (e.g., having the Cas9-sgRNA passed into the cell),
particularly where the cells to be transfected are hard-to-transfect cells, e.g., lymphoma cells and embryonic stem cells. Thus there is a need for a novel method and apparatus which facilitates passing the cell slurry through the cell deformation zone multiple times, whereby to increase the number of cells which are successfully transfected.
The present invention provides an optimized microfluidic approach to deliver plasmids encoding sgRNA and Cas9 efficiently into human cells, including
difficult-to-transfect cells, such as nonadherent lymphoma cells. More particularly, in another form of the present invention, there is provided a more efficient and portable CRIPSR-Cas9 microfluidic device 105 (sometimes referred to as a "Back and Forth Chip") which can enable new avenues of biomedical research and gene-targeting therapy.
Looking now at Figs. 13A, 14, 15 and 23-26, microfluidic device 105 is generally similar to the microfluidic device 5 discussed above, however, microfluidic device 105 is configured for repeated passage of a cell slurry through the flow chamber in a first direction, and then in a second, opposite direction, as will hereinafter be discussed in further detail. Microfluidic device 105 generally comprises a base chip 110 and a cover chip 115 (Fig. 13A) disposed over base chip 110. A plurality of structures extend between base chip 110 and cover chip 115, with cover chip 115 being spaced from base chip 110 such that a fluid (e.g., a suspension of cells) can be selectively passed through a flow chamber 120 located between base chip 110 and cover chip 115, as will hereinafter be discussed in further detail.
More particularly, and still looking at Figs. 13A, 14 and 15, flow chamber 120 comprises a first port 125 located at one end of flow chamber 120 and a second port 130 located at the opposite end of flow chamber 120. Flow chamber 120 comprises a plurality
of cell scatter zones 135 and a plurality of cell deformation zones 140 located between adjacent cell scatter zones 135.
Each cell scatter zone 135 comprises a plurality of cell scatter structures 145 which extend between base chip 110 and cover chip 115. Cell scatter structures 145 act to disperse and separate cells flowing through flow chamber 120, as will hereinafter be discussed. In one preferred form of the present invention, cell scatter structures 145 comprise a generally round cross-section.
Each cell deformation zone 140 comprises a plurality of cell deformation structures 150 which extend between base chip 110 and cover chip 115. Cell deformation structures 150 are spaced such that adjacent cell deformation structures 150 define a gap 155 (Fig. 13A) therebetween. Gap 155 is sized such that a cell which is flowed through gap 155 engages two cell deformation structures 150, whereby to mechanically constrict the cell between the cell deformation structures and momentarily mechanically deform the cell membrane, whereby to allow material (e.g., Cas9, sgRNA, etc.) to enter the cell, as will hereinafter be discussed. In one preferred form of the present invention, cell deformation structures 150 comprise a generally diamond-shaped cross-section.
As seen in the Figs. 12, 13A-13D, 14 and 15, the CRISPR-Cas9 microfluidic device 5 generally comprises
first port 125 and second port 130 separated by flow chamber 120. Flow chamber 120 comprises at least one cell deformation zone 140, wherein the at least one cell deformation zone 140 has a plurality of spaced cell deformation structures 150 between which cells must pass, and wherein the spacing between the cell deformation structures is such that deformation of the cells is required in order for the cells to pass between the cell deformation structures. Flow chamber 120 preferably also comprises at least one cell scatter zone 135, wherein the at least one cell scatter zone comprises a plurality of spaced cell scatter structures 145 between which the cells must pass, and wherein the spacing between the cell scatter structures is such that the cells are dispersed as they pass between the cell scatter structures. In one preferred form of the invention, flow chamber 120 comprises a plurality of cell deformation zones 140 and a plurality of cell scatter zones 135.
In use, in one form of the invention, and looking now at Fig. 12, a first syringe 160 and a second syringe 165 are attached to first port 125 and second port 130, respectively. At least one of the syringes contains a mixture of target cells and the material which is to be inserted into the target cells. The first and second syringes are then used to pass the mixture back and forth through flow chamber 120, with the target cells passing through the at least one cell
deformation zone 140 (and, where flow chamber 120 comprises at least one cell scatter zone 135, through the at least one cell scatter zone) . In this way, each target cell is subjected to repetitive
deformation in the presence of the material which is to be inserted into the target cells, whereby to increase the efficiency of cell transformation.
Alternatively, in another form of the invention, and looking now at Figs. 19-22, first syringe 160 preferably comprises a suspension of target cells, and second syringe 165 preferably comprises the material which is to be inserted into the target cells. First syringe 160 and second syringe 165 are then used to insert their contents into flow chamber 120 so that the contents mix, and then the first and second syringes are worked in opposing directions (Fig. 19) so as to repeatedly cycle the mixture through the at least one cell deformation zone 140 (and, where flow chamber 120 comprises at least one cell scatter zone 135, through the at least one cell scatter zone) . See
Figs. 20-22. In this way, each target cell is
subjected to repetitive deformation whereby to
increase the efficiency of cell transformation.
In another form of the invention, one or both of the first and second syringes may be replaced by alternative fluid delivery mechanisms (e.g., a pump, an elastic reservoir, a pipette, a vacuum, mechanical,
electronic, heat, magnetic or optically-powered pushing or pulling equipment, etc.) .
And in another form of the invention,
microfluidic device 105 may comprise a single port through which the target cells, and the material which is to be inserted into the target cells, is delivered into flow chamber 120. In this form of the invention, a single syringe (or other fluid delivery mechanism) may both insert and remove the target cells, and the material which is to be inserted into the target cells, to/from flow chamber 120.
And in another form of the present invention, and looking now at Figs. 27 and 28, microfluidic device 105 may be configured such that flow chamber 120 comprises a compound flow path, whereby to introduce turbulence into the cell slurry and better separate cells as they pass through cell deformation zone 140. By way of example but not limitation, inlet 125 may be fluidically connected to a plurality of entrances 170 which open onto flow chamber 120 at different
locations along flow chamber 120, whereby to introduce the cell slurry at different locations along the flow chamber .
The present invention provides numerous
advantages. Among other things:
(i) the present invention provides high-delivery efficiency of different macromolecules into different cell types, including hard-to-transfect lymphoma cells
and embryonic stem cells, while maintaining high cell viability;
(ii) the "back and forth" chip (microfluidic device 105) allows the target cells to be "squeezed" (for increased transfection) as many times as desired, by simply varying the number of times that the target cells are passed through the flow chamber;
(iii) the present invention provides highly- efficient genome editing and successful generation of specific gene-knockout cell lines by delivering plasmids encoding different sgRNAs and Cas9 into human cell lines, including nonadherent lymphoma cells - this sgRNA and Cas9 delivery method facilitates gene mutation correlation and gene therapy across different cell types, particularly difficult-to-transfect cell types which potentially enables many research and clinical applications;
(iv) using physical constriction to deform and shear cells for delivery has achieved high efficiency with low cell death rate; and
(v) the method of the present invention has the advantage of high throughput delivery of almost any macromolecule into almost any cell type - microfluidic platforms have the potential to serve as a broad-based universal delivery platform and provide the advantages of precise control over treatment conditions at the single-cell level with macro-scale throughput.
5 Cas9 Ribonucleoprotein Delivery Via
Microfluidic Cell-Deformation Chip For Human T-Cell Genome Editing And Immunotherapy The clustered regularly interspaced short
palindromic repeats (CRISPR) -Cas9 bacterial immunity system has been discovered and engineered for use as an efficient genome editing tool in a range of
organisms and applications. See L. Cong, F. A. Ran, D. Cox, S. Lin, R. Barretto, N. Habib, P. D. Hsu, X. Wu, W. Jiang, L. A. Marraffini, F. Zhang, Science
2013, 339, 819-823; P. Mali, L. Yang, K. M. Esvelt, J. Aach, M. Guell, J. E. DiCarlo, J. E. Norville, G. M. Church, Science 2013, 339, 823-826; and P. D. Hsu, E. S. Lander, F. Zhang, Cell 2014, 157, 1262-1278. In the two-component system, a single-guide RNA (sgRNA) directs the Cas9 nuclease to generate site-specific double-strand breaks (DSBs) for targeted gene
inactivation or modification. See L. Cong, F. A. Ran,
D. Cox, S. Lin, R. Barretto, N. Habib, P. D. Hsu, X. Wu, W. Jiang, L. A. Marraffini , F. Zhang, Science
2013, 339, 819-823; P. Mali, L. Yang, K. M. Esvelt, J. Aach, M. Guell, J. E. DiCarlo, J. E. Norville, G. M. Church, Science 2013, 339, 823-826. The ability to perturb and edit the genome in a precise and targeted manner is crucial to understanding genetic
contributions to biology and disease. See P. D. Hsu,
E. S. Lander, F. Zhang, Cell 2014, 157, 1262-1278; K. High, P. D. Gregory, C. Gersbach, Nat Med 2014, 20,
476-477} D. B. Cox, R. J. Piatt, F. Zhang, Nat Med
2015, 21, 121-131. The system has been used to correct disease-causing mutations in a flexible and affordable manner and enables new avenues of gene therapy in human therapeutics. See K. High, P. D.
Gregory, C. Gersbach, Nat Med 2014, 20, 476-477; D. B.
Cox, R. J. Piatt, F. Zhang, Nat Med 2015, 21, 121-131;
G. Schwank, B. K. Koo, V. Sasselli, J. F. Dekkers, I.
Heo, T. Demircan, N. Sasaki, S. Boymans, E. Cuppen, C. K. van der Ent, E. E. Nieuwenhuis, J. M. Beekman, H.
Clevers, Cell Stem Cell 2013, 13, 653-658; Y. Wu, D.
Liang, Y. Wang, M. Bai, W. Tang, S. Bao, Z. Yan, D.
Li, J. Li, Cell Stem Cell 2013, 13, 659-662; H. Yin,
W. Xue, S. Chen, R. L. Bogorad, E. Benedetti, M.
Grompe, V. Koteliansky, P. A. Sharp, T. Jacks, D. G.
Anderson, Nat Biotechnol 2014, 32, 551-553; J. L.
Gori, P. D. Hsu, M. L. Maeder, S. Shen, G. G.
Welstead, D. Bumcrot, Hum Gene Ther 2015, 26, 443-451; and H. Yin, C. Q. Song, J. R. Dorkin, L. J. Zhu, Y. Li, Q. Wu, A. Park, J. Yang, S. Suresh, A. Bizhanova,
A. Gupta, M. F. Bolukbasi, S. Walsh, R. L. Bogorad, G.
Gao, Z. Weng, Y. Dong, V. Koteliansky, S. A. Wolfe, R.
Langer, W. Xue, D. G. Anderson, Nat Biotechnol 2016,
34, 328-333.
T-cell genome editing holds great promise for immunotherapies for cancer, HIV, primary immune deficiencies, and autoimmune diseases, but genetic manipulation of human T cells with high efficency has
been challenging. The CRISPR-Cas9 technology
facilitates genome editing in many cell types, but its efficiency has been limited in difficult-to-transfect cells such as primary human T cells. Delivery poses a great challenge when utilizing a CRISPR-Cas9 based gene editing strategy, especially in human primary T cells. See L. Li, Z. Y. He, X. W. Wei, G. P. Gao, Y. Q. Wei, Hum Gene Ther 2015, 26, 452-462. Hence improved tools are desirable to efficiently target and edit genes to modulate T-cell function and correct disease-associated mutations.
The appropriate delivery system is critical to guarantee efficient genome editing in the targeted cells or organisms. Cas9 and sgRNA can be encoded within the plasmid DNA of viral or nonviral vectors for delivery into cells. However, plasmid-mediated delivery can result in the uncontrolled integration of the DNA sequence into the host genome and unwanted immune responses. See H. Hemmi, 0. Takeuchi, T.
Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K.
Hoshino, H. Wagner, K. Takeda, S. Akira, Nature 2000, 408, 740-745; H. Wagner, Immunity 2001, 14, 499-502. Furthermore, the prolonged and excess expression of Cas9 and sgRNA from plasmid DNA can worsen off-target cleavage effects. See Y. Fu, J. A. Foden, C. Khayter,
M. L. Maeder, D. Reyon, J. K. Joung, J. D. Sander, Nat Biotechnol 2013, 31, 822-826; V. Pattanayak, S. Lin, J. P. Guilinger, E. Ma, J. A. Doudna, D. R. Liu, Nat
Biotechnol 2013, 31, 839-843; P. D. Hsu, D. A. Scott, J. A. Weinstein, F. A. Ran, S. Konermann, V. Agarwala, Y. Li, E. J. Fine, X. Wu, 0. Shalem, T. J. Cradick, L. A. Marraffini, G. Bao, F. Zhang, Nat Biotechnol 2013, 31, 827-832; and S. W. Cho, S. Kim, Y. Kim, J. Kweon,
H. S. Kim, S. Bae, J. S. Kim, Genome Res 2014, 24, 132-141. Using the Cas9/sgRNA ribonucleoprotein (RNP) complex for delivery provides an alternative means of reducing off-target effects and avoiding unwanted plasmid integration. Electroporation of Cas9 RNPs has been achieved for efficient genome editing in
different cell types. See S. Kim, D. Kim, S. W. Cho, J. Kim, J. S. Kim, Genome Res 2014, 24, 1012-1019; and S. Lin, B. T. Staahl, R. K. Alia, J. A. Doudna, Elife 2014, 3, e04766. However, the electroporation method can induce cell damage with a high impact on cell viability. Mediators, such as lipid nanoparticles , cell-penetrating peptides and self-assembled DNA nanoclews, reportedly assist in the delivery of Cas9 and sgRNA for gene disruption. See J. A. Zuris, D. B.
Thompson, Y. Shu, J. P. Guilinger, J. L. Bessen, J. H. Hu, M. L. Maeder, J. K. Joung, Z. Y. Chen, D. R. Liu, Nat Biotechnol 2015, 33, 73-80; M. Wang, J. A. Zuris, F. Meng, H. Rees, S. Sun, P. Deng, Y. Han, X. Gao, D. Pouli, Q. Wu, I. Georgakoudi, D. R. Liu, Q. Xu, Proc
Natl Acad Sci U S A 2016; S. Ramakrishna, A. B. Kwaku Dad, J. Beloor, R. Gopalappa, S. K. Lee, H. Kim,
Genome Res 2014, 24, 1020-1027; and W. Sun, W. Ji, J.
M. Hall, Q. Hu, C. Wang, C. L. Beisel, Z. Gu, Angew Chem Int Ed Engl 2015, 54, 12029-12033. In these methods, the delivery efficiency is often dependent on the cell type, and the endosome escape mechanism most of these methods rely on is often inefficient, which do not serve for primary T cells. Therefore, the development of new Cas9 RNP delivery methods with high delivery efficiency and cell viability in human T cells remains highly desirable.
To this end, in another form of the present invention, there is provided a novel microfluidic cell deformation-based method and apparatus for delivering Cas9 ribonucleoprotein (RNP) complexes to different cell types for efficient genome editing, including hard-to-transfect human primary CD4+ T cells. In this form of the present invention, a novel microfluidic device uses physical constrictions to deform and shear cells to generate transient membrane holes that facilitate passive diffusion of delivery materials into the cytosol in a similar manner to the novel microfluidic devices 5, 105 discussed above. By improving the performance of microfluidic devices, the present invention achieves efficient and precise genome editing with reduced off-target effects by the delivery of Cas9 RNPs into cells. Using the novel microfluidic device of the present invention, knock-in genome modifications were achieved in human primary T cells by targeting PD-1 (PDCD-1 ) , a validated target
for tumor immunotherapy. Collectively, microfluidic cell deformation-based Cas9 RNP delivery provides a plasmid-free and transfection reagent-free method for use in different cell types, particularly in hard-to- transfect cells. Finally, the novel method and apparatus of the present invention can facilitate Cas9 RNP-directed genome editing and support the
utilization of gene therapy as a human therapeutics tool .
More particularly, it has been recognized that rapid mechanical deformation of cells can produce transient membrane disruptions or holes that
facilitate passive diffusion of material into the cytosol. See A. Sharei, J. Zoldan, A. Adamo, W. Y. Sim, N. Cho, E. Jackson, S. Mao, S. Schneider, M. J.
Han, A. Lytton-Jean, P. A. Basto, S. Jhunjhunwala, J. Lee, D. A. Heller, J. W. Kang, G. C. Hartoularos, K. S. Kim, D. G. Anderson, R. Langer, K. F. Jensen, Proc Natl Acad Sci U S A 2013, 110, 2082-2087. The novel membrane deformation-based microfluidic devices of the present invention have the advantage of high- throughput delivery of almost any macromolecule into almost any cell type. See X. Han, Z. Liu, M. C. Jo, K. Zhang, Y. Li, Z. Zeng, N. Li, Y. Zu, L. Qin, Sci Adv 2015, 1, el500454; and A. Sharei, J. Zoldan, A.
Adamo, W. Y. Sim, N. Cho, E. Jackson, S. Mao, S.
Schneider, M. J. Han, A. Lytton-Jean, P. A. Basto, S. Jhunjhunwala, J. Lee, D. A. Heller, J. W. Kang, G. C.
Hartoularos, K. S. Kim, D. G. Anderson, R. Langer, K. F. Jensen, Proc Natl Acad Sci U S A 2013, 110, 2082- 2087. With the advantages of broad applicability across different cell types, the novel method and apparatus of the present invention can serve as a broad-based universal delivery platform with
macroscale throughput and precise control over
treatment conditions at the single-cell level. As discussed above, microfluidic devices 5, 105 can be used to successfully deliver plasmids encoding Cas9 and sgRNA into different cell types and to achieve efficient genome editing. In another form of the invention, and looking now at Fig. 31A, there is shown another novel microfluidic device 205 formed in accordance with the present invention. Novel
microfluidic device 205 is generally similar to the aforementioned microfluidic devices 5, 105, however, microfluidic device 205 has been optimized for
improved delivery efficiency of Cas9 RNPs into
different cell types, including human primary CD4+ T cells. Sequence and biochemical analyses has
demonstrated that Cas9 RNP delivery using microfluidic device 205 achieved highly efficient genome editing and reduced off-target effects related to plasmid transfection (see Fig. 31D) . Furthermore, knock-in genome modifications in primary T cells were achieved in programmed cell death protein 1 (PD-1 or PDCD-1), a validated target for tumor immunotherapy. Thus, the
novel delivery method and apparatus of the present invention can facilitate Cas9 RNP-directed genome editing and therapeutic genome engineering
applications .
To improve efficiency, the design of microfluidic device 205 has been optimized based on the principle that rapid mechanical deformation of the cell causes transient membrane disruption or holes that facilitate the passive diffusion of material into the cell cytosol. See A. Sharei, J. Zoldan, A. Adamo, W. Y.
Sim, N. Cho, E. Jackson, S. Mao, S. Schneider, M. J. Han, A. Lytton-Jean, P. A. Basto, S. Jhunjhunwala, J. Lee, D. A. Heller, J. W. Kang, G. C. Hartoularos, K. S. Kim, D. G. Anderson, R. Langer, K. F. Jensen, Proc Natl Acad Sci U S A 2013, 110, 2082-2087. As
discussed above, constriction design (i.e., the arrangement and shape of cell deformation structures 50, 150) and the dimensions (i.e., the size of cell deformation structures 50, 150 and the width of gaps 55, 155) are key factors that affect delivery
efficiency. With microfluidic device 205, the
constriction shape (i.e., the shape of the gap between adjacent cell deformation structures) has been
modified to a curved tunnel in which cell deformation can occur to an enhanced degree over an extended time, as will hereinafter be discussed in further detail.
More particularly, and looking now at Figs. 31A and X1B, microfluidic device 205 generally comprises a
base chip 210 and a cover chip 215 disposed over, and spaced from, base chip 210, whereby to define a flow chamber 220 therebetween. An inlet 225 is fluidically connected to one end of flow chamber 220 and an outlet 230 is fluidically connected to the opposite end of flow chamber 220 such that a cell slurry may be flowed from inlet 225, through flow chamber 220 to outlet 230, as will hereinafter be discussed.
Flow chamber 220 generally comprises one or more cell scatter zones 235 and one or more cell
deformation zones 240. Cell scatter zones 235
comprise a plurality of cell scatter structures 245 extending between base chip 210 and cover chip 215. In one preferred form of the present invention, cell scatter structures 245 comprise a generally circular cross-section. Cell deformation zones 240 comprise a plurality of cell deformation structures 250. Cell deformation structures 250 preferably comprise an "X"- shaped (or "star shaped") cross-section (see Fig. 31B) and are arranged such that adjacent cell deformation structures 250 define a curved tunnel 255
therebetween .
In use, a slurry of cells is introduced into inlet 225 (e.g., using a syringe pump), whereby to enter flow chamber 220. The slurry of cells flows through one or more cell scatter zones 235, contacting cell scatter structures 245, whereby to better
separate the cells in the cell slurry. The cells then
enter one or more cell deformation zones 240 and an individual cell is drawn into each curved tunnel 255 between adjacent cell deformation structures 250, whereby to momentarily mechanically deform the cell, causing transient membrane disruption that facilitates passive diffusion of material into the cell cytosol. It will be appreciated that the material (s) which is to be passed into the cell (e.g., Cas9 RNP) is
preferably present in the cell slurry in an
appropriate concentration so as to facilitate cell uptake of the material (s) during transient membrane disruption .
Flow velocity simulation was applied to curved tunnel 255 through which the cells passed (Fig. 36) .
Microfluidic device 205 is preferably fabricated with standard polydimethylsiloxane (PDMS)
microfluidics technology and each chip comprises 10 cell deformation zones 240 that form
microconstrictions (i.e., curved tunnels 255) . To optimize the chip performance, cell deformation structures 250 were arranged horizontally and
vertically to form various curved tunnels 255 (Fig. 31C) . In an experiment, suspended cells were applied to microfluidic device 205 through Tygon® tubing connected to inlet 225, and fluid flow was controlled by a syringe pump (not shown) . A series of test deliveries of fluorescein isothiocyanate (FITC)- labeled 70-kDa dextran molecules into human luminal-
like SK-BR-3 breast cancer cells were performed.
Parameters including constriction width (i.e., the width of curved tunnels 255) and fluid flow rates were chosen based on previous experiments. The
constriction width of curved tunnel 255 varied from 4 pm to 8 pm and the flow rate was set at 150 μΐ/min. The delivery efficiency and cell viability were calculated for different structure arrangements, forming various arrangements of curved tunnels 255 in arrays 1-4 (Fig. 31D) . The delivery efficiency of 70- kDa dextran varied from about 60%-70% in the array 1-4 designs. To achieve higher delivery efficiency, the number of cell deformation zones 240 disposed along flow chamber 220 was increased to 10 in order to attain greater than 90% delivery efficiency of 70-kDa dextran (Fig. 31D) . The cell recovery rates after delivery exceeded 90% for all of the designs (Fig. 37) . However, higher delivery efficiency was often accompanied by lower cell viability using the
mechanical delivery method of this form of the
invention, which could influence the future
application of the method for different purposes.
To investigate the adaptability of the novel method and apparatus of the present invention for Cas9 RNP delivery, in another experiment, fluorescent labeled dextran molecules and short interfering RNAs (siRNA) were selected to simulate protein and RNA delivery. Adherent SK-BR-3 and non-adherent
neutrophil-like HL-60 cells were initially chosen to assess the delivery ability of the chip across
different cell types. FITC-labeled 70-kDa dextran molecules or siRNAs were delivered separately into the two cell lines with an efficiency greater than 90%
(Fig. 32A and Figs. 38 and 39) . Further, the
efficiency of the co-delivery of Cascade Blue-labeled dextran and FITC-labeled siRNA in these cells was greater than 80% (Figs. 32A and 32B) . One of the most significant advantages of microfluidic device 205 is that it has the potential to solve problems related to the use of cells that are difficult to transfect.
Primary T cells, the well-known, hard-to-transfect cells, were chosen for the delivery tests. Because primary T cells are less than 10 pm in size, the constriction width of curved tunnel 255 was varied from 2 pm to 4 pm. Even in the hard-to-transfect primary T cells, greater than 80% delivery efficiency was achieved for dextran and 90% delivery efficiency was achieved for siRNA (Fig. 32A and Figs. 38 and 39) .
The efficiency of the co-delivery of dextran and siRNA was greater than 70% (Figs. 32A and 32B) , indicating successful application of the present invention with hard-to-transfect cells. It will be appreciated that the delivery parameters of the present invention may be optimized to improve the delivery performance with respect to other specific cell types.
After the initial dextran and siRNA delivery experiments, another experiment was performed to demonstrate use of the Alt-R CRISPR transactivating RNA (tracrRNA) and crRNA system for Cas9 RNP assembly and delivery (Fig. 31A) . The native bacterial CRISPR system in Streptococcus pyogenes requires a sequence- specific crRNA and a conserved tracrRNA, which
interact through partial homology to form a
crRNA : tracrRNA complex. See E. Deltcheva, K.
Chylinski, C. M. Sharma, K. Gonzales, Y. Chao, Z. A.
Pirzada, M. R. Eckert, J. Vogel, E. Charpentier, Nature 2011, 471, 602-607. The crRNA : tracrRNA complex guides and activates Cas9 to cleave double-stranded DNA targets. See M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna, E. Charpentier, Science 2012,
337, 816-821. The crRNA was designed to target a sequence within enhanced green fluorescent protein (EGFP) , and the recombinant Cas9 protein was fused with nuclear-localization signals (NLSs) and purified following overexpression in Escherichia
coli. It was first confirmed that the resulting
Cas9 /tracrRNA/crRNA complex was active in vitro by cleavage of a plasmid encoding EGFP (Fig. 40) . SK-BR- 3 cells stably expressing EGFP were then used to demonstrate the Cas9 RNP delivery and genome editing ability of microfluidic device 205. The Cas9 RNP complex was delivered into cells for 3 days and flow cytometric analyses were used to determine the
knockout efficiency of EGFP (Fig. 33A) . The delivery of Cas9 RNP-induced EGFP expression was abolished in a protein and RNA concentration-dependent manner. When the concentration of Cas9 RNP delivered to the cells increased from 0.25 to 2 μΜ, the number of EGFP positive cells decreased from 67.4% to 14.2% (Fig. 33B and Fig. 41) . As expected, EGFP expression was not affected in the negative control cells, to which only Cas9 nuclease was delivered. These data indicate that successful delivery of Cas9 RNPs using microfluidic device 205 and the achievement of highly efficient genome editing.
To determine whether the present invention is suitable for gene disruption and function analyses, another experiment was performed, in which Cas9 RNPs were delivered which target p38 MAPKs (p38 mitogen- activated protein kinases), a class of kinases that participate in a signaling cascade controlling
cellular responses to cytokines and stress, into human basal-like MDA-MB-231 and SUM-159 breast cancer cells.
See A. Cuenda, S. Rousseau, Biochim Biophys Acta 2007, 1773, 1358-1375. The cells were allowed to recover in culture for 3 days after delivery, followed by PCR amplification of the specific sgRNA target region. A surveyor mutation detection assay revealed substantial cleavage at the p38 MAPK locus, with a mutation frequency of about 43% in MDA-MB-231 cells and 47% in SUM-159 cells (Fig. 33C) . Small insertions and
deletions (indels), characteristic of error-prone DSB repair via nonhomologous end joining (NHEJ) , were observed at the target site through the sequencing of the PCR amplicons (Fig. 33D) . Western blotting analysis revealed that endogenous p38 expression was abolished compared with the control in both cell lines (Fig. 42), which indicated the delivery platform of the present invention was effective for gene
disruption and function analysis.
The CRISPR-Cas9 system can induce off-target mutations at sites that are highly homologous to on- target sites and cause unwanted chromosomal
rearrangements such as translocations. See Y. Fu, J. A. Foden, C. Khayter, M. L. Maeder, D. Reyon, J. K. Joung, J. D. Sander, Nat Biotechnol 2013, 31, 822-826;
V. Pattanayak, S. Lin, J. P. Guilinger, E. Ma, J. A. Doudna, D. R. Liu, Nat Biotechnol 2013, 31, 839-843; P. D. Hsu, D. A. Scott, J. A. Weinstein, F. A. Ran, S. Konermann, V. Agarwala, Y. Li, E. J. Fine, X. Wu, 0. Shalem, T. J. Cradick, L. A. Marraffini, G. Bao, F.
Zhang, Nat Biotechnol 2013, 31, 827-832; and S. W. Cho, S. Kim, Y. Kim, J. Kweon, H. S. Kim, S. Bae, J. S. Kim, Genome Res 2014, 24, 132-141. However, Cas9 RNP delivery has the advantage to reduce off-target effects compared with plasmid transfection for genome editing. See S. Kim, D. Kim, S. W. Cho, J. Kim, J. S. Kim, Genome Res 2014, 24, 1012-1019; and S.
Ramakrishna, A. B. Kwaku Dad, J. Beloor, R. Gopalappa,
S. K. Lee, H. Kim, Genome Res 2014, 24, 1020-1027. Thus, the off-target activities were evaluated
following the targeted delivery of Cas9 RNP to the p38 MAPK locus using microfluidic device 205 (Fig. 34A) . As expected, the off-target mutation frequencies in cells in which Cas9 RNP was delivered with
microfluidic device 205 were drastically lower than those treated with plasmid transfection, whereas the on-target mutation frequencies were comparable between the two groups. The ratio of on- to off-target activities was 6.3-fold (53.7/8.5) higher for p38 RNP delivery by microfluidic device 205 versus plasmid transfection, which indicated that chip-mediated Cas9 RNP delivery using microfluidic device 205 was an efficient and precise genome editing method (Figs. 34A and 34B) . Importantly, RNP delivery did not sacrifice genome-editing activities at on-target sites, while reducing off-target effects, which greatly benefits the application of CRISPR technology for therapeutic genome editing.
CRISPR-Cas9 technology for genome editing has been limited in primary human T cells. See K.
Schumann, S. Lin, E. Boyer, D. R. Simeonov, M.
Subramaniam, R. E. Gate, G. E. Haliburton, C. J. Ye, J. A. Bluestone, J. A. Doudna, A. Marson, Proc Natl
Acad Sci U S A 2015, 112, 10437-10442; P. K. Mandal, L. M. Ferreira, R. Collins, T. B. Meissner, C. L.
Boutwell , M. Friesen, V. Vrbanac, B. S. Garrison, A.
Stortchevoi, D. Bryder, K. Musunuru, H. Brand, A. M. Tager, T. M. Allen, M. E. Talkowski, D. J. Rossi, C. A. Cowan, Cell Stem Cell 2014, 15, 643-652. The ability to ablate key targets and correct pathogenic genome sequence in human T cells would have direct therapeutic applications, eventually allowing T cells to be edited ex vivo and then reintroduced into patients. See K. Schumann, S. Lin, E. Boyer, D. R. Simeonov, M. Subramaniam, R. E. Gate, G. E.
Haliburton, C. J. Ye, J. A. Bluestone, J. A. Doudna,
A. Marson, Proc Natl Acad Sci U S A 2015, 112, 10437- 10442. Hence, human CD4+ T cells were chosen to investigate whether chip-mediated Cas9 RNP delivery using microfluidic device 205 could improve genome editing in these hard-to-transfect cells. Cas9 RNP and homologous donor DNA were co-delivered into human CD4+ T cells using microfluidic device 205 to test the knock-in genome modification frequency. The crRNA and homology-directed repair (HDR) template containing a novel Hindlll restriction enzyme cleavage site was designed to target the PD-1 (PDCD-1) locus (Fig. 35A) . PD-1 is a trans-membrane receptor found on the surface of T cells that negatively regulates immune responses by preventing the activation of T cells. See D. M. Pardoll, Nat Rev Cancer 2012, 12, 252-264. PD-1 inhibitors are approved for the treatment of
metastatic melanoma, and genetic deletion of PD-1 might prove useful in engineering T cells for cell-
based cancer immunotherapies. See L. B. John, C.
Devaud, C. P. Duong, C. S. Yong, P. A. Beavis, N. M. Haynes, M. T. Chow, M. J. Smyth, M. H. Kershaw, P. K. Darcy, Clin Cancer Res 2013, 19, 5636-5646; and S. L. Topalian, C. G. Drake, D. M. Pardoll, Cancer Cell
2015, 27, 450-461. PD-1 Cas9 RNPs co-delivered with the HDR template using microfluidic device 205
significantly reduced the percentage of cells with high PD-1 cell-surface expression relative to controls (Fig. 35B) . The specificity of the HDR templates for targeted nucleotide replacement were likewise
assessed. As expected, efficient PD-1 editing by PD-1 Cas9 RNPs was observed regardless of whether or not they were delivered using the PD-1 HDR template. In contrast, the Hindlll site was only incorporated into
PD-1 in the presence of both PD-1 Cas9 RNP and the PD- 1 HDR template, which indicated HDR-mediated knock-in genome modifications were achieved in human primary CD4+ T cells using the method and apparatus of the present invention (Fig. 35C) . Together, microfluidic cell deformation-based Cas9 RNP delivery provided efficient and precise genome editing in primary T cells, which holds great promise for therapeutic T- cell engineering and applications such as the
treatment of infection, autoimmunity, and cancer.
6 Materials And Methods
6.1 Materials And Reagents
SPR 220-7 photoresist was purchased from Rohm and Haas Electronic Materials. PDMS (GE 615 RTV) was purchased from Fisher Scientific. Tygon tubing was purchased from Saint-Gobain . Flat steel pins were purchased from New England Small Tube. Fetal bovine serum (FBS), trypsin, and penicillin-streptomycin were purchased from Fisher Scientific. Dulbecco's modified Eagle's medium (DMEM) , Ham's F-12 medium, RPMI-1640, Iscove's Modified Dulbecco's Medium (IMDM) and McCoy's
5a medium, insulin, hydrocortisone, and phosphate- buffered saline (PBS) were purchased from Life
Technologies. The single-stranded oligonucleotides of PD-1 HDR template were synthesized from Integrated DNA Technologies. The 20-bp target sequences of the indicated CRISPR crRNA were as follows: EGFP,
GGGCGAGGAGCTGTTCACCG; p38, AGGAGAGGCCCACGTTCTAC ; PD-1, CGACTGGCCAGGGCGCCTGT . The 20-bp off-target sequences of guide RNA targeting p38 were AGGGGAGACCCAGGATCTAC . The primers used for PCR amplification of target regions were as follows: p38-FP, AGTCTGCGGGGTCGCGG; p38-RP, CACACAGAGCCATAGGCGCC; p38-off-target-FP,
TTACAGATAGCAGAGAAGAAGGCAGGTG; p38-off-target-RP,
AAGGTCTTTCAGAGCCAGGGC; PD-l-FP, GGGGCTCATCCCATCCTTAG; PD-l-RP, TCTCTGCTCACTGCTGTGGC.
6.2 Chip Design And Fabrication
The microfluidic pattern of microfluidic device 205 was designed with AutoCAD (Autodesk) . Each cell deformation zone 240 of each microfluidic device 205 preferably comprises 10 arrays of structures (i.e., cell deformation structures 250) forming curved tunnel cell passages (i.e., curved tunnels 255) . The final design of microfluidic device 205 preferably comprises 10 repeats of identical cell deformation zones 240. The constriction width of curved tunnel 255 preferably varies from 4 pm to 8 pm for SK-BR-3, HL-60, MDA-MB-
231 and SUM-159 cells; and from 2 pm to 4 pm for primary T cells.
Microfluidic device 205 was fabricated according to standard photolithography and soft lithography procedures. The negative photoresist SU8-3025
(MicroChem) pattern on the silicon wafer was
fabricated with a photomask. The silicon wafer was then silanized with trimethylchlorosilane (Thermo Scientific) to facilitate polydimethylsiloxane (PDMS) mold release. PDMS prepolymer (Dow Corning) was poured onto the silicon wafer and cured at 80°C for 1 h. Holes were punched in the PDMS (i.e., for inlets 225 and outlets 230), and oxygen plasma treatment was used to chemically bond the PDMS mold (the base chip) to a glass slide (the cover chip) .
6.3 Cell Culture
SK-BR-3 cells were grown in McCoy's 5a Medium supplemented with 10% FBS and 1% penicillin- streptomycin in a humidified atmosphere of 5% C02/95% air at 37°C. HL-60 cells were cultured in IMDM with FBS to a final concentration of 20%. MDA-MB-231 cells were grown in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin. SUM159 cells were grown in Ham's F-12 medium supplemented with 5% FBS, 1%
penicillin-streptomycin, insulin (5 mg/ml), and hydrocortisone (1 mg/ml) .
Human CD4+ T-cells were purchased from PRECISION FOR MEDICINE (negatively selected, 12812) . The T cells were activated in RPMI-1640 medium supplemented with 10% FBS, 1% penicillin/streptomycin, Hepes (5 mmol/L), Glutamax (2 mmol/L), 2-mercaptoethanol (50 μπιοΙ/L), nonessential amino acids (5 mmol/L) and sodium pyruvate (5 mmol/L) . After delivery via microfluidic device 205, the medium was supplemented with 40 IU/mL IL-2. For delivery of Cas9 RNP via microfluidic device 205, the primary CD4+ T cells were pre-activated on CD3 (UCHT1; BD Pharmingen) and CD28 (CD28.2; BD Pharmingen) coated plates for 48 h.
Plates were coated with 10 g/mL CD3 and CD28 in PBS for at least 2 h at 37 °C.
6.4 Cas9 RNP Assembly And Delivery Procedure
Recombinant S. pyogenes Cas9 nuclease was
purchased from Integrated DNA Technologies, which was
purified from E. coli strain expressing codon
optimized Cas9 with 1 N-terminal nuclear localization sequence (NLS), 2 C-terminal NLSs, and a C-terminal 6- His tag. For Cas9 RNP assembly, the Alt-R CRISPR-Cas9 System (Integrated DNA Technologies) was used, which consists of Alt-R S.p. Cas9 Nuclease 3NLS combined with Alt-R CRISPR crRNA and tracrRNA. The crRNA and tracrRNA were suspended in Nuclease-Free Duplex Buffer and mixed equally to a final duplex concentration (for example, 1 μΜ) . The two RNA oligos mixture was heated at 95 °C for 5 min and then allowed to cool to room temperature (20-25 °C) . The Cas9 nuclease was diluted in Opti-MEM medium (Life Technologies) to a working concentration (for example, 1 μΜ) and incubated with complexed crRNA : tracrRNA oligos at room temperature for 5 min to assemble the RNP complexes.
Flow chamber 220 of microfluidic device 205 were wetted with PBS and blocked with 1% bovine serum albumin (BSA) in PBS for 10 min. Cells were first suspended in the desired volume of Opti-MEM medium and then mixed with amount of Cas9 RNP complexes and loaded into a plastic Tygon tube with a 5-mL syringe. The tube was connected to inlet 225 by a flat steel pin. During the flow experiments, a syringe pump controlled the rate of the fluid flow through
microfluidic device 205. Treated cells were incubated in a 37°C incubator for 20 min to recover before further treatment .
6.5 Flow Cytometry And Western Blotting
Flow cytometric analysis was conducted after EGFP Cas9 RNP-mediated knockout - cells were allowed to recover in culture for 3 days, followed by analysis of EGFP fluorescence with a BD LSRFortessa cell analyzer. Cell-surface staining was performed with PD- 1-PE (EH12.2H7; Biolegend) for 15 min on ice. Cells were kept at 4 °C throughout the staining procedure until cell sorting to minimize antibody-mediated
internalization and degradation of the antibody.
For Western blotting after p38 Cas9 RNP-mediated knockout, cells were allowed to recover in culture for 3 days. The primary antibodies used were anti-p38 (ab31828, Abeam) and anti-tubulin (ab7291, Abeam) .
6.6 Mutation Detection Assay, TA Cloning, And Sequencing
Genomic DNA was extracted using the PureLink Genomic DNA Mini Kit (K1820-00, Life Technologies) according to the manufacturer's instructions. PCR amplicons of nuclease target sites were generated and analyzed for the presence of mismatch mutations using the Transgenomic Surveyor Mutation Detection Kit
(Integrated DNA Technologies) according to the
manufacturer's instructions. Briefly, PCR amplicons of sgRNA target regions were denatured by heating for 10 min at 95°C, annealed to form heteroduplex DNA
using a thermocycler from 95° to 25°C at -0.3°C/s, digested with Surveyor Nuclease S for 2 hours at 42°C, and separated by 1% agarose gel electrophoresis. For sequence analysis, PCR products corresponding to genomic modifications were cloned into pCR4-T0P0 vector using the TOPO TA Cloning Kit (Life
Technologies) . Cloned products were sequenced using the M13 primer. 6.7 Analysis Of HDR By Hindiii Restriction
Digestion
The HDR templates for PD-1 are single-stranded oligonucleotides complementary (antisense strand) to the target sequence and contain a Hindiii restriction sequence along with 90-nt homology arms. Upon
successful HDR, the respective PAM sites are deleted, which should prevent recutting of the edited site by the Cas9 RNPs . The PD-1 HDR template additionally causes a frameshift and nonsense mutation by replacing 12 nt with 11 nt . PD-1 HDR template is 5 ' -AAC CTG ACC
TGG GAC AGT TTC CCT TCC GCT CAC CTC CGC CTG AGC AGT GGA GAA GGC GGC ACT CTG GTG GGG CTG CTC CAG GCA TGC AGA TAA TGA AAG CTT CTG GCC AGT CGT CTG GGC GGT GCT ACA ACT GGG CTG GCG GCC AGG ATG GTT CTT AGG TAG GTG GGG TCG GCG GTC AGG TGT CCC AGA GC-3 ' .
To test for successful introduction of the
Hindiii site into the PD-1 locus, the targeted region was amplified by PCR. The PCR products were purified
and then digested by the enzyme Hindlll for 2h at 37 °C. The product was resolved on 1.5% agarose gel. The percentage of HDR was calculated using the
following equation: (b + c/a + b + c) χ 100, where a is the band intensity of DNA substrate and b and c are the cleavage products.
7 Microfluidic Device For Mechanical Deformation Of The Cell Membrane Of Hard-To- Transfect Human Hematopoietic Stem Cells
As discussed above, novel microfluidic device 5 comprises a cell deformation zone 40 disposed within a flow chamber 20. Cell deformation zone 40 comprises a plurality of cell deformation structures 50 which are spaced such that adjacent cell deformation structures
50 define gaps 55 therebetween. Gap 55 is sized such that a cell which is flowed through gap 55 engages the cell deformation structures 50, whereby to
mechanically constrict the cell between the cell deformation structures and momentarily mechanically deform the cell membrane, whereby to allow material (e.g., Cas9, sgRNA, etc.) to enter the cell.
Novel microfluidic devices 105 and 205 (with cell deformation zones 140 and 240, respectively; flow chambers 120 and 220, respectively; cell deformation structures 150, 250, respectively; and gap 155 and curved tunnel 255, respectively) utilize similar concepts .
However, it has been found that it can be
particularly challenging to pass material into certain types of cells. By way of example but not limitation, human hematopoietic stem cells (HSCs) can be
challenging to pass material into the cell using the novel deformation structures 50 of microfluidic device 5 discussed above (and/or using the novel deformation structures 150 of microfluidic device 105 discussed above and/or using the novel deformation structures 250 of microfluidic device 205 discussed above) .
To that end, and looking now at Fig. 43, there is shown another novel microfluidic device 305 formed in accordance with the present invention. Microfluidic device 305 is generally similar to the aforementioned microfluidic devices 5, 105 and 205, except that in this form of the invention, deformation structures 50, 150 and/or 250 are replaced by novel deformation structures 350, and cell deformation zones 40, 140 and 240 have been modified, as will hereinafter be
discussed in further detail.
More particularly, and looking now at Figs. 44 and 45, deformation structures 350 generally comprise an "inverted funnel" shape comprising a base portion 352 and a riser portion 353. In a preferred form of the invention, deformation structures 350 are
approximately 10 pm in height (i.e., they extend approximately 10 pm between the base chip and the cover chip, see Fig. 44) .
Looking next at Fig. 46, deformation zone 340 differs from the aforementioned deformation zones 40, 140 and 240 in that the flow chambers 20, 120 and 240 have been replaced by a plurality of flow channels 342, with each flow channel being defined by an uninterrupted side wall 343 disposed on one side of the flow channel and a side wall 344 comprising at least one deformation structure 350 extending along the other side of the flow channel. Side walls 343 and 344 of flow channels 342 are spaced apart, and cell deformation structures 350 are sized, such that gaps 355 are optimized for the physical
characteristics of the target cell (e.g, for the human hematopoietic stem cell, a gap preferably of
approximately 2 pm) exists between the tip of riser portion 353 of a given deformation structure 350 and the opposing side wall 343 of a given flow channel 342.
As a result of this construction, when a cell (e.g., a human hematopoietic stem cell) is passed through microfluidic device 305 and enters a flow channel 342, the cell will contact the edge of riser portion 353 of a deformation structure 350 (Figs. 45 and 47) and squeeze through the gap 355 between the deformation structure and the opposing side wall of the flow channel, whereby to momentarily mechanically deform the cell membrane of the cell and allow
material to enter into the cell.
It has also been found that it may be desirable to form cell deformation structures 350 and/or
microfluidic device 305 (and/or the aforementioned cell deformation structures 50, 150 and/or 250, and/or microfluidic devices 5, 105 and/or 205) out of a silicon substrate, rather than out of a
polydimethylsiloxane (PMDS) substrate as disclosed above, so that the "sharpness" and rigidity of cell deformation structures 350 are enhanced; this can improve mechanical deformation of the cell membrane and hence increase the delivery efficiency of
materials into the cell.
To this end, in one preferred form of the
invention, microfluidic device 305 (and/or the
aforementioned microfluidic devices 5, 105 and/or 205) are preferably formed out of silicon rather than polydimethylsiloxane (PDMS) . Silicon allows the fabrication resolution of the device to be increased to nanoscale levels, which is helpful for achieving the desired cell constriction using cell deformation structures 350, while at the same time providing a more rigid and less deformable surface.
In one preferred form of the invention,
microfluidic device 305 is designed using AutoCAD (Autodesk), and then microfabrication is performed using a 500-um thickness silicon wafer as the
substrate. A layer of silicon oxide (SiC>2) , preferably 450 nm thick, is then deposited on the wafer by wet
thermal oxidation (1050 °C) . Then flow channels 342 are patterned on the S1O2 film by standard
photolithography using a NR9-500P negative photoresist (Futurrex Franklin, NJ, USA) and contact aligner
(K.Suss MA6 mask aligner) . Next, the channel pattern is transferred into the S1O2 layer by reactive ion etch (RIE) in CF4 plasma (Plasmatherm BatchTop, 15 seem CF4, 100 mTorr, 175W RF) . Then 10-μπι depth microchannels are etched into the silicon by Bosch based Deep
Silicon Etch (DSE) on an Inductively Coupled Plasma
Etcher (Plasma-Therm Versaline ICP) . The etching depth can be monitored using a Dektak 150 Optical Profilometer . The silicon substrate can then be etched by a metal-assisted chemical method in 10% HF, 122 mM H2O2 to form deformation structures 350.
Using silicon as the substrate material to form microfluidic device 305 (and/or the aforementioned microfluidic devices 5, 105 and/or 205) instead of polydimethylsiloxane (PDMS) provides at least two significant advantages. First, the Young's modulus of silicon is approximately 106 times higher than that of polydimethylsiloxane (PDMS), which provides a larger interaction pressure when the cell is passing through gaps 355 formed between deformation structures 350 and side walls 343 of flow channels 342. Second, the fabrication resolution of a given cell deformation structure 350 can be improved down to nanoscale levels, which PDMS cannot achieve.
It should also be appreciated that, if desired, cell deformation structures 350 may be replaced by (or supplemented by) other deformation structures having geometries different from the inverted funnel
structure shown in Figs. 43-47, configured to optimize the membrane porosity (the number and/or size of membrane openings) of a specific cell type while maintaining cell membrane integrity and cell
viability. By way of example but not limitation, such other deformation structures may be configured to enhance cell porosity by capitalizing on the various factors which affect cell porosity, e.g., the
interactive force distribution, a change in cell orientation, the amount of contact time with the cell membrane, etc. By way of further example but not limitation, and looking now at Figs. 48 and 49, there is shown an alternative cell deformation structure 350A which generally comprise a curved "hill" (or "dune") shape. In this form of the invention, cell deformation structures 350A are disposed on side walls
344 such that the apex or crown of a given cell deformation structure 350A is spaced from the opposing side wall 343 by a gap 355 (e.g., a 2 pm gap), whereby to permit a cell passing through the flow channel to be mechanically deformed as the cell engages cell deformation structure 350A and squeezes past, whereby to allow passage of material into the cell.
54 -
8 Microfluidic Device For Mechanical Deformation Of The Cell Membrane Comprising Controlled Chemotaxis Gradient For On-Chip Downstream Analysis
In addition to the foregoing, it has also been found that it may be desirable to provide a
microfluidic device which is configured to (i) mechanically deform the cell membrane of a cell so as to facilitate delivery of material into a cell, e.g., for delivery of siRNA into a cell for gene silencing, and (ii) allow for on-chip cell migration assay (e.g., for studying the phenotype transition of cancer cells to gain insights into invasiveness and migration at a tumor site) .
To this end, and looking now at Fig. 50, there is shown a novel microfluidic device 405. Microfluidic device 405 utilizes the same general principles employed with microfluidic devices 5, 105, 205, 305 discussed above (i.e., mechanical constriction of the cell in order to temporarily disrupt the cell membrane so as to allow the passage of material into the cell), but microfluidic device 405 differs from the
aforementioned microfluidic devices 5, 105, 205 and 305 in several significant aspects.
More particularly, microfluidic device 405 generally comprises a base chip 410, a cover chip (not shown) disposed over base chip 410 (i.e., so as to form, in conjunction with one another, a closed
chamber), and a plurality of structures which extend between base chip 410 and the cover chip, such that a fluid (e.g., a suspension of cells) can be selectively passed through a flow chamber 420 located between base chip 410 and the cover chip, as will hereinafter be discussed in further detail. Flow chamber 420 is divided into two sections: a cell deformation section 422 and a cell migration section 423.
More particularly, and still looking at Fig. 50, flow chamber 420 comprises one or more inlets 425A,
425B, 425C located at one end of flow chamber 420, and one or more outlets 430A, 430B and 430C located at the opposite end of flow chamber 420. Inlet 425B is in fluid communication with cell deformation section 422, which is in fluid communication with cell migration section 423, whereby to allow a fluid (e.g., a
suspension of cells) to be passed through cell
deformation section 422 and into/through cell
migration section 423, as will hereinafter be
discussed in further detail. Inlets 420A and 420C, and outlets 430A, 430B and 430C, are in fluid
communication with cell migration section 423.
Cell deformation section 422 preferably comprises two or more cell deformation structures 450. Each cell deformation structure 450 preferably comprises a
"reverse-fishbone" geometry, i.e., each cell
deformation structure 450 comprises a body 452 and a plurality of angled arms 453 directed away from body
452 (Figs. 50, 51 and 53) . Cell deformation
structures 450 are preferably placed adjacent to one another in cell deformation section 422 such that their respective angled arms 453 are separated by a gaps 455. In one preferred form of the present invention, gaps 455 are 5 pm wide, however, it should be appreciated that gaps 455 may be larger or smaller depending on the cells that are to be passed through cell deformation section 422 (e.g., gap 455 may comprise a gap of between 2 pm and 10 pm) .
It should also be appreciated that the plurality of angled arms 453 of a given cell deformation
structure 450 may be angled away from the longitudinal axis of body 452 of that particular cell deformation structure at various angles. By way of example but not limitation, in one preferred form of the
invention, arms 453 are angled away from the
longitudinal axis of body 452 of a particular cell deformation structure 450 at an angle of approximately 135 degrees. Alternatively, arms 453 may be angled away from the longitudinal axis of body 452 of a particular cell deformation structure 450 at angles of 45 degrees, 90 degrees, etc. Furthermore, if desired, a given cell deformation structure 450 may comprise arms 453 that are angled away from the longitudinal axis of body 452 at different angles than adjacent arms 453.
Cell migration section 423 preferably comprises a plurality of traps 424 (Fig. 50) disposed along the length of flow channel 420, preferably in-line with gaps 455 defined by cell deformation structures 450 of cell deformation section 422. Each trap 424 comprises a concave structure defined by a pair of arms 426 separated by a central gap 427. By way of example but not limitation, arms 426 can be spaced/curved so as to define a concavity 426A having an opening that is 30 pm across and a gap 427 that is 2 pm wide (see Fig.
52) . Cell migration section 423 also preferably comprises a plurality of migration chambers 428
(e.g., 40 migration chambers 428) disposed
perpendicular to the flow path of fluid flowing through flow chamber 420, with each migration chamber
428 comprising a plurality of migration microchannels
429 (e.g., 20 migration microchannels 429) . See Figs. 50 and 52. Note that Figs. 50 and 52 are meant to be schematic in nature, in the sense that migration chambers 428 are shown generalized in Fig. 50 and microchannels 429 are shown generalized in Fig. 52. In one preferred form of the invention, migration microchannels 429 are approximately 8 pm wide and 500 pm long.
In use, a fluid (e.g., a suspension of cells, such as MDA-MB-231 cancer cells) is passed into inlet 425B so as to enter cell deformation section 422 and squeeze past gaps 455 between adjacent cell
deformation structures 450. As this occurs,
individual cells are mechanically deformed by contact with adjacent arms 453 on either side of gaps 455, whereby to allow material (e.g., siRNA) present in the fluid to pass through the cell membrane and into the cell, whereby to alter the cell.
After the cells have passed through cell
deformation section 422, the cells enter cell
migration section 423 and are captured by traps 424. In the case of MDA-MB-231 cancer cells, approximately
2 cells can be captured in each trap 424, however, it should also be appreciated that traps 424 may be sized to capture more or less cells, and/or traps 424 may be differently configured depending upon what cells are to be contained in the traps.
Microfluidic device 405 (containing altered cells now trapped within traps 424) is then incubated for a desired period (e.g., 2-3 days) with fresh media being perfused into the cell (e.g., by gravity flow) to allow the cells to grow. A chemotaxis-inducing gradient can then be introduced into microfluidic device 405. By way of example but not limitation, a chemotaxis-inducing gradient may be introduced by passing a chemotactic agent (e.g., fetal bovine serum, FBS) into one or more of inlets 425A and 425C) , whereby to promote the migration of cells out of traps 424 and into migration microchannels 429. It should be appreciated that the migration characteristics of
altered cells may differ from the migration
characteristics of unaltered control cells, and/or altered cells may exhibit different morphology than unaltered control cells.
Modifications Of The Preferred Embodiments
It should be understood that many additional changes in the details, materials, steps and
arrangements of parts, which have been herein
described and illustrated in order to explain the nature of the present invention, may be made by those skilled in the art while still remaining within the principles and scope of the invention.
Claims
1. A system for transfecting cells, the system comprising :
a microfluidic device comprising:
a housing having a flow passageway formed therein, the flow passageway comprising a port; and a cell deformation zone formed within the flow passageway, the cell deformation zone comprising a plurality of flow channels, wherein the plurality of flow channels each comprise a first wall and a second wall, wherein the first wall and the second wall are spaced apart so as to define a flow path therebetween;
at least one cell deformation structure extending away from the first wall of a given flow channel into the flow path of that flow channel, the at least one cell deformation structure being spaced away from the second wall of that flow channel such that a gap is disposed between the at least one cell deformation structure and the second wall, wherein the gap is sized such that a cell passing through the gap is mechanically deformed as the cell passes through that gap.
2. A system according to claim 1 wherein the at least one cell deformation structure comprises a base portion adjacent to the first wall of the flow channel and a riser portion adjacent to the gap between the at
least one cell deformation structure and the second wall of the flow channel, and further wherein the base portion is wider than the riser portion.
3. A system according to claim 2 wherein the at least one cell deformation structure has a funnel shaped cross-sectional configuration.
4. A system according to claim 2 wherein the riser portion of the at least one cell deformation structure comprises a sharp edge extending into the flow channel .
5. A system according to claim 4 wherein the sharp edge is defined by a first surface of the riser portion that is substantially parallel to the
longitudinal axis of the flow channel and a second surface of the riser which is substantially
perpendicular to the longitudinal axis of the flow channel .
6. A system according to claim 1 wherein each of the plurality of flow channels comprises at least two cell deformation structures, whereby to provide at least two gaps within each flow channel.
7. A system according to claim 1 wherein each of the gaps has a width of between about 2 pm and about 8 pm.
8. A system according to claim 7 wherein each of the gaps has a width of about 2 pm.
9. A system according to claim 1 wherein the housing comprises a substrate, and further wherein the substrate comprises silicon.
10. A system according to claim 9 wherein the substrate further comprises a coating of S1O2.
11. A system according to claim 9 wherein the at least one cell deformation structure is formed on the substrate .
12. A system according to claim 1 further comprising (i) a plurality of cells to be transfected, and (ii) the material to be transfected into the plurality of cells.
13. A system according to claim 12 wherein the plurality of cells to be transfected, and the material to be transfected into the plurality of cells, are combined in a fluid for introduction into the port.
14. A system according to claim 12 wherein the housing further comprises a second port, wherein the cell deformation zone is formed within the flow passageway between the port and the second port, and wherein the plurality of cells to be transfected are configured to be introduced into the port, and the material to be transfected into the plurality of cells are configured to be introduced into the second port.
15. A system according to claim 12 wherein the material to be transfected into the plurality of cells comprise plasmids.
16. A system according to claim 15 wherein the plasmids comprise plasmids encoding sgRNA and plasmids encoding Cas9 protein.
17. A system according to claim 15 wherein the plasmids further comprise plasmids encoding crRNA and plasmids encoding tracrRNA.
18. A system according to claim 12 wherein the material to be transfected into the plurality of cells comprise siRNA.
19. A method for transfecting cells, the method comprising :
providing a system for transfecting cells, the system comprising:
a microfluidic device comprising:
a housing having a flow passageway formed therein, the flow passageway comprising a port; and
a cell deformation zone formed within the flow passageway, the cell deformation zone
comprising a plurality of flow channels, wherein the plurality of flow channels each comprise a first wall and a second wall, wherein the first wall and the second wall are spaced apart so as to define a flow path therebetween;
at least one cell deformation structure extending away from the first wall of a given flow channel into the flow path of that flow channel, the at least one cell deformation structure being spaced away from the second wall of that flow channel such a gap is
disposed between the at least one cell deformation structure and the second wall, wherein the gap is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap; and
introducing into the flow passageway (i) a plurality of cells to be transfected, and (ii) the material to be transfected into the plurality of cells .
20. A method according to claim 19 wherein the plurality of cells to be transfected, and the material to be transfected into the plurality of cells, are combined in a fluid for introduction into the port.
21. A method according to claim 19 wherein the housing further comprises a second port, and wherein the cell deformation zone is formed within the flow passageway between the port and the second port.
22. A method according to claim 21 wherein the system further comprises a cell injection/reception mechanism connectable to the port and a second cell injection/reception mechanism connectable to the second port .
23. A method according to claim 19 wherein the material to be transfected into the plurality of cells comprise plasmids.
24. A method according to claim 23 wherein the plasmids comprise plasmids encoding sgRNA and plasmids encoding Cas9 protein.
25. A method according to claim 24 wherein plasmids further comprise plasmids encoding crRNA plasmids encoding tracrRNA.
26. A method according to claim 19 wherein the material to be transfected into the plurality of cells comprise siRNA.
27. A system for transfecting cells, the system comprising :
a microfluidic device comprising:
a housing having a flow passageway formed therein, the flow passageway comprising a port;
a cell deformation zone formed within the flow passageway, the cell deformation zone comprising a plurality of cell deformation structures defining a plurality of gaps therebetween, wherein each of the cell deformation structures comprises a body and a plurality of arms extending away from the body, wherein at least two cell deformation structures are arranged parallel to one another such that a plurality of gaps exist between the plurality of arms of the cell deformation structures, and further wherein each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap.
28. A system according to claim 27 further comprising :
a plurality of cells to be transfected; and
material to be transfected into the plurality of cells, wherein the material to be transfected into the plurality of cells.
29. A system according to claim 28 wherein the material to be transfected into the plurality of cells comprises plasmids encoding sgRNA and plasmids
encoding Cas9 protein.
30. A system according to claim 28 wherein the material to be transfected into the plurality of cells further comprises plasmids encoding crRNA and plasmids encoding tracrRNA.
31. A system according to claim 28 wherein the material to be transfected into the plurality of cells comprise siRNA.
32. A system according to claim 27 wherein each of the plurality of arms extend away from the
longitudinal axis of the body of each of the cell deformation structures at an angle of approximately 45 degrees .
33. A system according to claim 27 wherein each of the plurality of arms extend away from the
longitudinal axis of the body of each of the cell
deformation structures at an angle of approximately 90 degrees .
34. A system according to claim 27 wherein each of the plurality of arms extend away from the
longitudinal axis of the body of each of the cell deformation structures at an angle of approximately 135 degrees.
35. A system according to claim 27 wherein each of the plurality of gaps has a width of between about 2 pm and about 8 pm.
36. A system according to claim 27 wherein each of the plurality of gaps has a width of about 5 pm.
37. A system according to claim 27 wherein the housing comprises a substrate and a cover mountable to the substrate.
38. A system according to claim 37 wherein the substrate comprises silicon.
39. A system according to claim 38 wherein the substrate comprises a coating of S1O2.
40. A system according to claim 38 wherein the plurality of cell deformation structures are formed on the substrate.
41. A method for transfecting cells, the method comprising :
providing a system for transfecting cells, the system comprising:
a microfluidic device comprising:
a housing having a flow passageway formed therein, the flow passageway comprising a port;
a cell deformation zone formed within the flow passageway, the cell deformation zone
comprising a plurality of cell deformation structures defining a plurality of gaps therebetween, wherein each of the cell deformation structures comprises a body and a plurality of arms extending away from the body, wherein at least two cell deformation structures are arranged parallel to one another such that a plurality of gaps exist between the plurality of arms of the cell deformation structures, and further wherein each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap;
a plurality of cells to be transfected; and
material to be transfected into the plurality of cells; and
introducing into the flow passageway a plurality of cells to be transfected, and the material to be transfected into the plurality of cells.
42. A method according to claim 41 wherein the material to be transfected into the plurality of cells comprises plasmids encoding sgRNA and plasmids
encoding Cas9 protein.
43. A method according to claim 41 wherein the material to be transfected into the plurality of cells further comprises plasmids encoding crRNA and plasmids encoding tracrRNA.
44. A method according to claim 41 wherein the material to be transfected into the plurality of cells comprises siRNA.
45. A method according to claim 41 wherein the plurality of cells to be transfected, and the material to be transfected into the plurality of cells, are combined in a slurry for introduction into the flow passageway .
46. A system for transfecting cells, the system comprising :
a microfluidic device comprising:
a housing having a flow chamber formed therein, the flow chamber comprising at least one inlet ;
a cell deformation section formed within the flow chamber, the cell deformation section comprising a plurality of cell deformation structures defining a plurality of gaps therebetween, and wherein each of the plurality of gaps is sized such that a cell passing through a gap is mechanically deformed as the cell passes through that gap;
a cell migration section formed within the flow chamber and fluidically connected to the cell deformation section, the cell migration section comprising a plurality of traps arrayed serially along the flow chamber and a plurality of migration
microchannels disposed perpendicular to the
longitudinal axis of the flow chamber and fluidically connected to the flow chamber.
47. A system according to claim 46 wherein the plurality of traps comprise a concave structure.
48. A system according to claim 47 wherein the concave structure is defined by a pair of curved arms spaced apart so as to define an entrance to the concavity at one end of the concavity and an exit from the concavity at the opposite end of the concavity.
49. A system according to claim 48 wherein the entrance to the concavity is approximately 30 pm wide.
50. A system according to claim 48 wherein the exit from the concavity is approximately 2 pm wide.
51. A system according to claim 46 wherein the plurality of migration microchannels are approximately 8 pm wide and approximately 500 pm in length.
52. A system according to claim 46 further comprising a chemotactic gradient across at least a portion of the cell migration section.
53. A method for transfecting and
chemotactically separating cells, the method
comprising :
providing a system for transfecting cells, the system comprising:
a microfluidic device comprising: a housing having a flow chamber formed therein, the flow chamber comprising at least one inlet ;
a cell deformation section formed within the flow chamber, the cell deformation section comprising a plurality of cell deformation structures defining a plurality of gaps therebetween, and wherein each of the plurality of gaps is sized such that a cell
passing through a gap is mechanically deformed as the cell passes through that gap;
a cell migration section formed within the flow chamber and fluidically connected to the cell deformation section, the cell migration section comprising a plurality of traps arrayed serially along the flow chamber and a plurality of migration
microchannels disposed perpendicular to the
longitudinal axis of the flow chamber and fluidically connected to the flow chamber;
a plurality of cells to be transfected; and material to be transfected into the plurality of cells; and
introducing into the flow chamber a plurality of cells to be transfected, and the material to be transfected into the plurality of cells;
flowing the plurality of cells to be transfected, and the material to be transfected into the plurality of cells, through the cell deformation section such that some of the cells are transfected;
flowing the plurality of cells to be transfected, the material to be transfected into the plurality of cells, and the transfected cells into the cell
migration section such that at least some of the cells are retained in the cell migration section;
incubating the housing for a pre-determined period of time;
introducing a chemotactic gradient into the cell migration section; and
allowing the cells retained in the cell migration section to migrate into one or more of the migration microchannels along the chemotactic gradient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2017/059758 WO2019089034A1 (en) | 2017-11-02 | 2017-11-02 | Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2017/059758 WO2019089034A1 (en) | 2017-11-02 | 2017-11-02 | Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019089034A1 true WO2019089034A1 (en) | 2019-05-09 |
Family
ID=66332714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/059758 WO2019089034A1 (en) | 2017-11-02 | 2017-11-02 | Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2019089034A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022207717A1 (en) * | 2021-04-01 | 2022-10-06 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Multistage device and method for intracellular delivery |
CN115254214A (en) * | 2022-06-29 | 2022-11-01 | 中国科学院精密测量科学与技术创新研究院 | Microfluidic channel, microfluidic chip and biochemical molecule delivery method |
WO2022240846A1 (en) * | 2021-05-10 | 2022-11-17 | Sqz Biotechnologies Company | Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof |
WO2023020545A1 (en) * | 2021-08-17 | 2023-02-23 | 南京微欣利康科技有限公司 | Microfluidic chip and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160193605A1 (en) * | 2013-08-16 | 2016-07-07 | Massachusetts Institute Of Technology | Selective Delivery of Material to Cells |
US9586810B2 (en) * | 2010-07-30 | 2017-03-07 | Sony Corporation | Polymeric substrate having an etched-glass-like surface and a microfluidic chip made of said polymeric substrate |
WO2017070169A1 (en) * | 2015-10-19 | 2017-04-27 | The Methodist Hospital | Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation |
-
2017
- 2017-11-02 WO PCT/US2017/059758 patent/WO2019089034A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9586810B2 (en) * | 2010-07-30 | 2017-03-07 | Sony Corporation | Polymeric substrate having an etched-glass-like surface and a microfluidic chip made of said polymeric substrate |
US20160193605A1 (en) * | 2013-08-16 | 2016-07-07 | Massachusetts Institute Of Technology | Selective Delivery of Material to Cells |
WO2017070169A1 (en) * | 2015-10-19 | 2017-04-27 | The Methodist Hospital | Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation |
Non-Patent Citations (3)
Title |
---|
HAN, X ET AL.: "Cas9 Ribonucleoprotein Delivery via Microfluidic Cell -Deformation Chip for Human T- Cell Genome Editing and Immunotherapy", ADVANCED SCIENCE NEWS, vol. 1, 16 January 2017 (2017-01-16), pages 1 - 6, XP055614692 * |
HAN, X ET AL.: "CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation", MICROTECHNOLOGY, vol. 1, 14 August 2015 (2015-08-14), pages 1 - 9, XP002766823, DOI: doi:10.1126/sciadv.1500454 * |
LIU, Z ET AL.: "Integrated Microfluidic System for Gene Silencing and Cell Migration", ADVANCED BIOSYSTEMS, vol. 1, no. 6, June 2017 (2017-06-01), pages 1 - 14, XP055614687 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022207717A1 (en) * | 2021-04-01 | 2022-10-06 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Multistage device and method for intracellular delivery |
WO2022240846A1 (en) * | 2021-05-10 | 2022-11-17 | Sqz Biotechnologies Company | Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof |
WO2023020545A1 (en) * | 2021-08-17 | 2023-02-23 | 南京微欣利康科技有限公司 | Microfluidic chip and application thereof |
CN115254214A (en) * | 2022-06-29 | 2022-11-01 | 中国科学院精密测量科学与技术创新研究院 | Microfluidic channel, microfluidic chip and biochemical molecule delivery method |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180327706A1 (en) | Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation | |
Han et al. | CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation | |
JP7209671B2 (en) | Methods and compositions for modifying genomic DNA | |
JP6885876B2 (en) | Methods and Compositions for Modifying Genomic DNA | |
AU2016206870B2 (en) | Gene editing through microfluidic delivery | |
Sahin et al. | mRNA-based therapeutics—developing a new class of drugs | |
WO2019089034A1 (en) | Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation | |
Dixit et al. | Massively-parallelized, deterministic mechanoporation for intracellular delivery | |
ES2777305T3 (en) | Trophoblastic glycoprotein-specific chimeric antigen receptors (5T4, TPBG) for cancer immunotherapy | |
JP2019520844A (en) | Methods and compositions for modifying genomic DNA | |
CN110785489A (en) | Compositions and methods for gene editing in T cells using CRISPR/Cpf1 | |
CN113337402A (en) | Intracellular delivery | |
Gerer et al. | Electroporation of mRNA as universal technology platform to transfect a variety of primary cells with antigens and functional proteins | |
JP7313363B2 (en) | Intracellular delivery and methods therefore | |
CN114901808A (en) | Method for producing CAR-T cells | |
Narayanavari et al. | Sleeping Beauty transposon vectors for therapeutic applications: advances and challenges | |
Hur et al. | Genetically stable and scalable nanoengineering of human primary T cells via cell mechanoporation | |
Sung et al. | The practical application of gene vectors in cancer therapy | |
Chen et al. | Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies | |
Quach et al. | Viral Generation, Packaging, and Transduction on a Digital Microfluidic Platform | |
Liu et al. | Nanochannel Electro‐Injection as a Versatile Platform for Efficient RNA/DNA Programming on Dendritic Cells | |
WO2021061900A1 (en) | A method for development ally- activating a cell | |
CN113226336A (en) | Method for delivering gene in cell | |
Haritha et al. | Gene Therapy–A review | |
US20220218971A1 (en) | Nanoprojection devices as well as methods of making and using such devices |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17930991 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17930991 Country of ref document: EP Kind code of ref document: A1 |